<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>

    <title>Pocket Medicine, 8e</title>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
  <link rel="stylesheet" type="text/css" href="../stylesheet.css"/>
<link rel="stylesheet" type="text/css" href="../page_styles.css"/>

  


<link href="../calibreHtmlOutBasicCss.css" type="text/css" rel="stylesheet" />

</head>
<body>

<div class="calibreMeta">
  <div class="calibreMetaTitle">
  
  
    
    <h1>
      <a href="../../j09u21sl.html">Pocket Medicine (Pocket Notebook Series)
</a>
    </h1>
    
    
  
  </div>
  <div class="calibreMetaAuthor">
    Marc Sabatine

  </div>
</div>

<div class="calibreMain">

  <div class="calibreEbookContent">
    
      <div class="calibreEbNavTop">
        
          <a href="part0009.html" class="calibreAPrev">previous page
</a>
        

        
          <a href="part0011.html" class="calibreANext">next page
</a>
        
      </div>
    

    
<h2 class="ct"><a id="h55" class="calibre8"></a><a id="page_4-1" class="calibre8"></a><a href="part0003.html#rh62" class="calibre8">ACID-BASE DISTURBANCES</a></h2>
<p class="h1cr">G<small class="calibre31">ENERAL</small></p>
<p class="h">Definitions</p>
<p class="noindent1">• <b class="calibre7">Acidemia</b> → pH &lt;7.36, <b class="calibre7">alkalemia</b> → pH &gt;7.44; pH = 6.10 + log([HCO<sub class="calibre10">3</sub>]/[0.03xPCO<sub class="calibre10">2</sub>])</p>
<p class="noindent1">• <b class="calibre7">Acidosis</b> → process that ↑ [H<sup class="calibre19">+</sup>] or ↓ pH by ↓ HCO<sub class="calibre10">3</sub> or ↑ PaCO<sub class="calibre10">2</sub></p>
<p class="noindent1">• <b class="calibre7">Alkalosis</b> → process that ↓ [H<sup class="calibre19">+</sup>] or ↑ pH by ↑ HCO<sub class="calibre10">3</sub> or ↓ PaCO<sub class="calibre10">2</sub></p>
<p class="noindent1">• Primary disorders: metabolic acidosis or alkalosis, respiratory acidosis or alkalosis</p>
<p class="noindent1">• Compensation</p>
<p class="noindent2">Respiratory: hyper/hypoventilation alters P<sub class="calibre10">a</sub>CO<sub class="calibre10">2</sub> to counteract 1° metabolic process</p>
<p class="noindent2">Renal: excretion/retention of H<sup class="calibre19">+</sup>/HCO<sub class="calibre10">3</sub><sup class="calibre19">–</sup> to counteract 1° respiratory process</p>
<p class="noindent2">Respiratory compensation occurs in mins-hrs; renal compensation takes days</p>
<p class="noindent2"><i class="calibre6">Compensation usually never fully corrects pH</i>; if pH normal, consider mixed disorder</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Consequences of Severe Acid-Base Disturbances</b> <span class="sm">(<i class="calibre6">NEJM</i> 1998;338:26 &amp; 107)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Organ System</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Acidemia (pH</b> &lt;<b class="calibre7">7.20)</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Alkalemia (pH</b> &gt;<b class="calibre7">7.60)</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Cardiovascular</p></td>
<td class="th1"><p class="tbody">↓ contractility, arteriolar vasodilation</p>
<p class="tbody">↓ MAP &amp; CO; ↓ response to catecholamines</p>
<p class="tbody">↑ risk of arrhythmias</p></td>
<td class="th1"><p class="tbody">Arteriolar vasoconstriction</p>
<p class="tbody">↓ coronary blood flow</p>
<p class="tbody">↑ risk of arrhythmias</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Respiratory</p></td>
<td class="th1"><p class="tbody">Hyperventilation, ↓ resp. muscle strength</p></td>
<td class="th1"><p class="tbody">Hypoventilation</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Metabolic</p></td>
<td class="th1"><p class="tbody">↑ K (resp. &gt; metab.), insulin resistance</p></td>
<td class="th1"><p class="tbody">↓ K, Ca, Mg, PO<sub class="calibre17">4</sub></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Neurologic</p></td>
<td class="th1"><p class="tbody">Δ MS</p></td>
<td class="th1"><p class="tbody">Δ MS, seizures, tetany</p></td>
</tr>
</tbody>
</table>
<p class="h">Workup <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2014;371:1434)</span></p>
<p class="noindent1">• <b class="calibre7">Traditional or physiologic approach</b> (Brønsted-Lowry definition of acids &amp; bases)</p>
<p class="noindent2">Determine <b class="calibre7">primary disorder:</b> ✓ pH, P<sub class="calibre10">a</sub>CO<sub class="calibre10">2</sub>, HCO<sub class="calibre10">3</sub></p>
<p class="noindent2">Determine if <b class="calibre7">degree of compensation</b> is appropriate</p>
<p class="imaget"><img src="../images/00060.jpeg" alt="" class="calibre5"/></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre18"/>
<col class="calibre13"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Compensation for Acid-Base Disorders</b> <span class="sm">(<i class="calibre6">NEJM</i> 2014;371:1434)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Primary Disorder</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Expected Compensation</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Metabolic acidosis</p></td>
<td class="th1"><p class="tbody">↓ P<sub class="calibre17">a</sub>CO<sub class="calibre17">2</sub> = 1.2 × ΔHCO<sub class="calibre17">3</sub></p>
<p class="tbody">or P<sub class="calibre17">a</sub>CO<sub class="calibre17">2</sub> = (1.5 × HCO<sub class="calibre17">3</sub>) + 8 ± 2 (Winters’ formula)</p>
<p class="tbody">(also, P<sub class="calibre17">a</sub>CO<sub class="calibre17">2</sub> ≈ last 2 digits of pH)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Metabolic alkalosis</p></td>
<td class="th1"><p class="tbody">↑ P<sub class="calibre17">a</sub>CO<sub class="calibre17">2</sub> = 0.7 × ΔHCO<sub class="calibre17">3</sub></p>
<p class="tbody">or P<sub class="calibre17">a</sub>CO<sub class="calibre17">2</sub> = 0.7 (HCO<sub class="calibre17">3</sub>–24) + 40 ± 2 or HCO<sub class="calibre17">3</sub> + 15</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Acute respiratory acidosis</p></td>
<td class="th1"><p class="tbody">↑ HCO<sub class="calibre17">3</sub> = 0.1 × ΔP<sub class="calibre17">a</sub>CO<sub class="calibre17">2</sub></p>
<p class="tbody">(also, ↓ pH = 0.008 × ΔP<sub class="calibre17">a</sub>CO<sub class="calibre17">2</sub>)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Chronic respiratory acidosis</p></td>
<td class="th1"><p class="tbody">↑ HCO<sub class="calibre17">3</sub> = 0.35 × ΔP<sub class="calibre17">a</sub>CO<sub class="calibre17">2</sub></p>
<p class="tbody">(also, ↓ pH = 0.003 × ΔP<sub class="calibre17">a</sub>CO<sub class="calibre17">2</sub>)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Acute respiratory alkalosis</p></td>
<td class="th1"><p class="tbody">↓ HCO<sub class="calibre17">3</sub> = 0.2 × ΔP<sub class="calibre17">a</sub>CO<sub class="calibre17">2</sub></p>
<p class="tbody">(also, ↑ pH = 0.008 × ΔP<sub class="calibre17">a</sub>CO<sub class="calibre17">2</sub>)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Chronic respiratory alkalosis</p></td>
<td class="th1"><p class="tbody">↓ HCO<sub class="calibre17">3</sub> = 0.4 × ΔP<sub class="calibre17">a</sub>CO<sub class="calibre17">2</sub></p></td>
</tr>
</tbody>
</table>
<p class="noindent1">• <b class="calibre7">Alternative approaches</b></p>
<p class="noindent2">Base excess/deficit <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;378:1419)</span></p>
<p class="noindent2">Strong ion difference or “Stewart Method” <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2014;371:1821)</span></p>
<p class="h">Mixed disorders (more than one primary disorder at the same time)</p>
<p class="noindent1">• If compensation less or greater than predicted, may be two disorders:</p>
<p class="noindent2">P<sub class="calibre10">a</sub>CO<sub class="calibre10">2</sub> too low → concomitant 1° resp. alk.; P<sub class="calibre10">a</sub>CO<sub class="calibre10">2</sub> too high → concomitant 1° resp. acid.</p>
<p class="noindent2">HCO<sub class="calibre10">3</sub> too low → concomitant 1° met. acid.; HCO<sub class="calibre10">3</sub> too high → concomitant 1° met. alk.</p>
<p class="noindent1">• Normal pH, <i class="calibre6">but...</i></p>
<p class="noindent2">↑ P<sub class="calibre10">a</sub>CO<sub class="calibre10">2</sub> + ↑ HCO<sub class="calibre10">3</sub> → resp. acid. + met. alk.</p>
<p class="noindent2">↓ P<sub class="calibre10">a</sub>CO<sub class="calibre10">2</sub> + ↓ HCO<sub class="calibre10">3</sub> → resp. alk. + met. acid.</p>
<p class="noindent2">Normal P<sub class="calibre10">a</sub>CO<sub class="calibre10">2</sub> &amp; HCO<sub class="calibre10">3</sub>, <i class="calibre6">but</i> ↑ AG → AG met. acid. + met. alk.</p>
<p class="noindent2">Normal P<sub class="calibre10">a</sub>CO<sub class="calibre10">2</sub>, HCO<sub class="calibre10">3</sub>, &amp; AG → no disturbance <i class="calibre6">or</i> non-AG met. acid. + met. alk.</p>
<p class="noindent1">• <i class="calibre6">Cannot</i> have resp. acid. (hypoventilation) and resp. alk. (hyperventilation) simultaneously</p>
<div class="cap">
<p class="caption"><a id="page_4-2" class="calibre4"></a><a id="fig4-1" class="calibre4"></a><b class="calibre7">Figure 4-1</b> Acid-base nomogram</p>
<p class="imagef1"><img src="../images/00061.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="tfn">(Adapted from Brenner BM, ed., <i class="calibre6">Brenner &amp; Rector’s The Kidney</i>, 8th ed., 2007; Ferri F, ed. <i class="calibre6">Practical Guide to the Care of the Medical Patient</i>, 7th ed., 2007)</p>
<p class="noindent1">• <b class="calibre7">ABG vs. VBG:</b> concordant for pH (~0.04), HCO<sub class="calibre10">3</sub> (~2 mEq) but <b class="calibre7">not</b> PCO<sub class="calibre10">2</sub> (~8±17 mmHg)</p>
<p class="noindent2">VBG can be used to <i class="calibre6">screen</i> for hypercarbia w/ PCO<sub class="calibre10">2</sub> cutoff ≥45 mmHg (100% Se),</p>
<p class="noindent2"><b class="calibre7">but</b> may not accurately assess <i class="calibre6">degree</i> of hypercarbia <span class="r1">(</span><span class="r2">Am J Emerg Med</span> <span class="r1">2012;30:896)</span></p>
<p class="h1cr">M<small class="calibre31">ETABOLIC</small> A<small class="calibre31">CIDOSIS</small></p>
<p class="h">Initial workup <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2014;371:1434)</span></p>
<p class="noindent1">• ✓ <b class="calibre7">anion gap</b> (AG) = Na<sup class="calibre19">+</sup> – (Cl<sup class="calibre19">–</sup> + HCO<sub class="calibre10">3</sub><sup class="calibre19">–</sup>) = unmeasured anions – unmeasured cations</p>
<p class="noindent2">If ↑ glc, use measured <i class="calibre6">not</i> corrected Na</p>
<p class="noindent2">Expected AG is [albumin] × 2.5 (ie, 10 if albumin is 4 g/dL, 7.5 if albumin is 3 g/dL)</p>
<p class="noindent2">↑ AG → ↑ unmeasured anions such as organic acids, phosphates, sulfates</p>
<p class="noindent2">↓ AG → ↓ alb or ↑ unmeasured cations (Ca, Mg, K, Li, Ig), bromide/iodine toxicity</p>
<p class="noindent1">• If ↑ AG, ✓ <b class="calibre7">delta-delta</b> (Δ/Δ = ΔAG/ΔHCO<sub class="calibre10">3</sub>) to assess if there is an additional metabolic</p>
<p class="noindent2">acid-base disturbance; ΔAG = (calculated AG – expected AG), ΔHCO<sub class="calibre10">3</sub> = (24 – HCO<sub class="calibre10">3</sub>)</p>
<p class="noindent3">Δ/Δ = 1–2 → pure AG metabolic acidosis</p>
<p class="noindent3">Δ/Δ &lt;1 → AG metabolic acidosis <i class="calibre6">and</i> simultaneous non-AG acidosis</p>
<p class="noindent3">Δ/Δ &gt;2 → AG metabolic acidosis <i class="calibre6">and</i> simultaneous metabolic alkalosis</p>
<p class="noindent3">For pure lactic acidosis Δ/Δ 1.6 b/c of slow lactate clearance</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Etiologies of AG Metabolic Acidosis</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Ketoacidosis</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Diabetes mellitus,</b> alcoholism, starvation <span class="sm">(<i class="calibre6">NEJM</i> 2015;372:546)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Lactic acidosis</b> <span class="sm">(<i class="calibre6">NEJM</i> 2014; 371:2309)</span></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Type A:</b> hypoxic (eg, shock, mesenteric ischemia, CO poisoning, cyanide)</p>
<p class="tbodyh"><b class="calibre7">Type B:</b> nonhypoxic. ↓ clearance (eg, hepatic dysfxn) or ↑ generation [eg, malig, EtOH, thiamine def., meds (metformin, NRTIs, salicylates, propylene glycol, propofol, isoniazid, linezolid)]</p>
<p class="tbodyh"><b class="calibre7"><small class="sm">D</small>-lactic acidosis:</b> short bowel syndrome → precip by glc ingest → metab by colonic bacteria to <small class="sm">d</small>-lactate; not detected by standard lactate assay</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Renal failure</b></p></td>
<td class="th1"><p class="tbodyh">Accumulation of organic anions (eg, phosphates, sulfates, etc.)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Ingestions</b></p>
<p class="tbodyh"><span class="sm">(<i class="calibre6">NEJM</i> 2020; 382:2544)</span></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Glycols:</b> <i class="calibre6">Ethylene</i> (antifreeze) → metab to glycolic and oxalic acids</p>
<p class="tbodyh"><i class="calibre6">Propylene</i> (pharmaceutical solvent, eg, IV diazepam, lorazepam, and phenobarbital; antifreeze) → lactic acidosis</p>
<p class="tbodyh"><i class="calibre6">Diethylene</i> (brake fluid) → diglycolic acid</p>
<p class="tbodyh"><b class="calibre7">5-oxoproline</b> (pyraglutamic acid): acetaminophen → ↑ organic acid 5- oxoproline in susceptible Pts (malnourished, female, renal failure)</p>
<p class="tbodyh"><b class="calibre7">Methanol</b> (windshield fluid, antifreeze, solvents, fuel): metab to formic acid</p>
<p class="tbodyh"><b class="calibre7">Aspirin</b>: early resp alkalosis (CNS stim) + late metab acidosis (impairs oxidative phosphorylation → inorganic acids (eg, ketones, lactate)</p></td>
</tr>
</tbody>
</table>
<p class="tfn">“GOLD MARK” = Glycols, Oxoproline, Lactic, D-Lactic, Methanol, ASA, Renal, Ketoacidosis</p>
<p class="h"><a id="page_4-3" class="calibre4"></a>Workup for AG metabolic acidosis <span class="r1">(</span><span class="r2">AJKD</span> <span class="r1">2021;78:A16)</span></p>
<p class="noindent1">• ✓ for <b class="calibre7">ketonuria</b> (dipstick acetoacetate) or plasma β-hydroxybutyrate (βOHB)</p>
<p class="noindent2">nb, urine acetoacetate often not present in early ketoacidosis due to shunting to βOHB; ∴ acetoacetate may later turn ⊕ but does not signify worsening disease</p>
<p class="noindent1">• If ⊖ ketones, ✓<b class="calibre7"> renal function, lactate, toxin screen, and osmolal gap</b></p>
<p class="noindent1">• If obtunded or ↑↑ AG, check <b class="calibre7">osmolal gap</b> (OG) = measured osmoles – calculated osmoles</p>
<p class="noindent2">Calculated osmoles = (2 × Na) + (glucose/18) + (BUN/2.8) (+ [EtOH/4.6] if ↑ EtOH level and want to test if other ingestions)</p>
<p class="noindent2">OG &gt;10 → suggests ingestion (see below) but lacks specificity (can be elevated in lactic acidosis, DKA, and alcoholic ketoacidosis due to acetone)</p>
<p class="noindent2">High-dose lorazepam (&gt;10 mg/h) a/w propylene glycol intoxication</p>
<p class="noindent2">OG &amp; AG vary based on timing, initially OG ↑, then ↓ w/ metabolism as AG ↑</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre28"/>
<col class="calibre28"/>
<col class="calibre20"/>
<col class="calibre26"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="4"><p class="tbodyc"><b class="calibre7">Ingestions</b> <span class="sm">(<i class="calibre6">NEJM</i> 2018;378:270)</span> Call poison control for guidance (800-222-1222)</p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">AG</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">OG</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Ingestion</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Other Manifestations</b></p></td>
</tr>
<tr class="calibre15">
<td rowspan="2" class="th1"><p class="tbodyc">↑</p></td>
<td rowspan="2" class="th1"><p class="tbodyc">nl</p></td>
<td class="th1"><p class="tbody">Acetaminophen</p></td>
<td class="th1"><p class="tbody">Hepatitis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Salicylates</p></td>
<td class="th1"><p class="tbody">Fever, tachycardia, tinnitus; met. acid. + resp. alkalosis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">↑</p></td>
<td class="th1"><p class="tbodyc">↑</p></td>
<td class="th1"><p class="tbody">Methanol</p></td>
<td class="th1"><p class="tbody">ΔMS, blurred vision, pupillary dilation, papilledema</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">↑</p></td>
<td class="th1"><p class="tbodyc">↑</p></td>
<td class="th1"><p class="tbody">Ethylene glycol</p></td>
<td class="th1"><p class="tbody">ΔMS, cardiopulm. failure, hypoCa. <b class="calibre7">Ca oxalate crystals</b> → AKI. Urine fluoresces under UV light.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">nl/↑</p></td>
<td class="th1"><p class="tbodyc">↑</p></td>
<td class="th1"><p class="tbody">Propylene glycol</p></td>
<td class="th1"><p class="tbody">AKI, liver injury</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">↑</p></td>
<td class="th1"><p class="tbodyc">nl/↑</p></td>
<td class="th1"><p class="tbody">Diethylene glycol</p></td>
<td class="th1"><p class="tbody">AKI, N/V, pancreatitis, neuropathy, lactic acidosis</p></td>
</tr>
<tr class="calibre15">
<td rowspan="2" class="th1"><p class="tbodyc">nl/↑</p></td>
<td rowspan="2" class="th1"><p class="tbodyc">↑</p></td>
<td class="th1"><p class="tbody">Isopropyl alcohol</p></td>
<td class="th1"><p class="tbody">ΔMS, fruity breath (acetone), pancreatitis, lactic acidosis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Ethanol</p></td>
<td class="th1"><p class="tbody">Alcoholic fetor, ΔMS, hepatitis; keto + lactic acidosis ± met. alk. (vomiting)</p></td>
</tr>
</tbody>
</table>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Etiologies of Non-AG Metabolic Acidosis</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">GI losses of HCO<sub class="calibre17">3</sub></b></p></td>
<td class="th1"><p class="tbody">Diarrhea, intestinal or pancreatic fistulas or drainage</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">RTAs</b></p></td>
<td class="th1"><p class="tbody"><i class="calibre6">See section on renal tubular acidoses below</i></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Early renal failure</b></p></td>
<td class="th1"><p class="tbody">Impaired generation of ammonia</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Ingestions</b></p></td>
<td class="th1"><p class="tbody">Acetazolamide, sevelamer, cholestyramine, toluene</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Dilutional</b></p></td>
<td class="th1"><p class="tbody">Due to rapid infusion of bicarbonate-free IV fluids</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Posthypocapnia</b></p></td>
<td class="th1"><p class="tbody">Respiratory alkalosis → renal wasting of HCO<sub class="calibre17">3</sub>; rapid correction of resp. alk. → transient acidosis until HCO<sub class="calibre17">3</sub> regenerated</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Ureteral diversion</b></p></td>
<td class="th1"><p class="tbody">Colonic Cl<sup class="calibre27">–</sup>/HCO<sub class="calibre17">3</sub><sup class="calibre27">–</sup> exchange, ammonium reabsorption</p></td>
</tr>
</tbody>
</table>
<p class="h">Workup for non-AG metabolic acidosis</p>
<p class="noindent1">• Evaluate history for causes (see above)</p>
<p class="noindent1">• ✓ <b class="calibre7">urine anion gap</b> (UAG) = (U<sub class="calibre10">Na</sub> + U<sub class="calibre10">K</sub>) – U<sub class="calibre10">Cl</sub></p>
<p class="noindent2">UAG = unmeasured anions – unmeasured cations; NH<sub class="calibre10">4</sub><sup class="calibre19">+</sup> is primary unmeasured cation (represented by U<sub class="calibre10">Cl</sub>). UAG is indirect assay for renal H<sup class="calibre19">+</sup> excretion.</p>
<p class="noindent1">• ⊖ UAG → ↑ renal NH<sub class="calibre10">4</sub><sup class="calibre19">+</sup> excretion → appropriate renal response to acidemia</p>
<p class="noindent2">Ddx: GI causes (diarrhea, fistulas, ureteral diversion), IV NS, ingestions</p>
<p class="noindent1">• ⊕ UAG → failure of kidneys to generate NH<sub class="calibre10">4</sub><sup class="calibre19">+</sup></p>
<p class="noindent2">Ddx: distal (type 1, usually ↓ K) or hypoaldo (type IV, usually ↑ K) RTA, early renal failure</p>
<p class="noindent1">• UAG unreliable in AKI/CKD, polyuria, Na depletion (U<sub class="calibre10">Na</sub> &lt;20), U<sub class="calibre10">pH</sub> &gt;6.5 &amp; HAGMA (causes ⊕ UAG b/c excretion of organic anions) and less useful in prox RTA as variable. Then use U<sub class="calibre10">Osm</sub> gap = measured U<sub class="calibre10">Osm</sub> – [2×(Na<sup class="calibre19">+</sup> + K<sup class="calibre19">+</sup>) + BUN + glc (mmol/L)]. U<sub class="calibre10">Osm</sub> gap &lt;40 mmol/L indicates impaired NH<sub class="calibre10">4</sub><sup class="calibre19">+</sup> excretion</p>
<p class="h">Renal tubular acidoses (RTAs) <span class="r1">(</span><span class="r2">Adv Ther</span> <span class="r1">2021;38:949)</span></p>
<p class="noindent1">• <b class="calibre7">Proximal</b> (Type II): ↓ proximal reabsorption of HCO<sub class="calibre10">3</sub></p>
<p class="noindent2">1° (Fanconi’s syndrome) = ↓ proximal reabsorption of HCO<sub class="calibre10">3</sub>, PO<sub class="calibre10">4</sub>, glc, amino acids</p>
<p class="noindent2">Acquired: paraprotein (MM, amyloidosis), metals (Pb, Cd, Hg, Cu), ↓ vit D, PNH, renal Tx</p>
<p class="noindent2">Meds: acetazolamide, aminoglycosides, ifosfamide, cisplatin, topiramate, tenofovir</p>
<p class="noindent1">• <b class="calibre7">Distal</b> (Type I): defective distal H<sup class="calibre19">+</sup> secretion</p>
<p class="noindent2">1°, autoimmune (Sjögren’s, RA, SLE), hypercalciuria, meds (ampho, Li, ifosfamide); normally a/w ↓ K; if with ↑ K → sickle cell, obstruction, renal transplant</p>
<p class="noindent1">• <b class="calibre7">Hypoaldo</b> (Type IV): hypoaldo → ↑ K → ↓ NH<sub class="calibre10">3</sub> synthesis → ↓ urine acid-carrying capacity</p>
<p class="noindent2">↓ renin: diabetic nephropathy, NSAIDs, chronic interstitial nephritis, calcineurin inh, HIV</p>
<p class="noindent2">↓ aldo production: 1° AI, ACEI/ARBs, heparin, severe illness, inherited (↓ 21-hydroxylase)</p>
<p class="noindent2">↓ response to aldosterone</p>
<p class="noindent2">Meds: K-sparing diuretics, TMP-SMX, pentamidine, calcineurin inhibitors</p>
<p class="noindent2">Tubulointerstitial disease: sickle cell, SLE, amyloid, DM</p>
<p class="noindent1">• Combined (Type III): rarely discussed or clinically relevant, also called juvenile RTA, has distal &amp; proximal features, can be due to carbonic anhydrase II deficiency</p>
<p class="imaget"><a id="page_4-4" class="calibre4"></a><img src="../images/00062.jpeg" alt="" class="calibre5"/></p>
<p class="tfn"><sup class="calibre22"><a id="rfn70-a" class="calibre8"></a>a</sup>Urine pH will rise above 5.3 in the setting of HCO<sub class="calibre24">3</sub> load</p>
<p class="tfn"><sup class="calibre22"><a id="rfn70-b" class="calibre8"></a>b</sup>Fe<sub class="calibre24">HCO3</sub> should be checked after an HCO<sub class="calibre24">3</sub> load</p>
<p class="tfn"><sup class="calibre22"><a id="rfn70-c" class="calibre8"></a>c</sup>See above for causes of distal RTA (Type I) associated with hyperkalemia</p>
<div class="cap">
<p class="caption"><a id="fig4-2" class="calibre4"></a><b class="calibre7">Figure 4-2</b> Approach to metabolic acidosis</p>
<p class="imagef1"><img src="../images/00063.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="h">Treatment of severe metabolic acidoses (pH &lt;7.2) <span class="r1">(</span><span class="r2">Nat Rev Nephrol</span> <span class="r1">2012;8:589)</span></p>
<p class="noindent1">• DKA: insulin, IVF, K repletion <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;372:546)</span>; AKA: dextrose, IVF, replete K, Mg, PO<sub class="calibre10">4</sub></p>
<p class="noindent1">• Lactic acidosis: treat underlying condition, avoid vasoconstrictors, avoid “Type B” meds</p>
<p class="noindent1">• Renal failure: hemodialysis</p>
<p class="noindent1">• Methanol &amp; ethylene glycol: fomepizole (20 mg/dL), vit. B<sub class="calibre10">1</sub> &amp; B<sub class="calibre10">6</sub> (ethylene glycol), folate (methanol), dialysis (if AKI, VS unstable, vision Δ or &gt;50 mg/dL) <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;378:270)</span></p>
<p class="noindent1">• Alkali therapy: if pH &lt;7.1 or &lt;7.2 and co-existing AKI (may ↓ mortality; <span class="r2">Lancet</span><span class="r1"> 2018;392:31</span>)</p>
<p class="noindent1">• NaHCO<sub class="calibre10">3</sub>: amps by IV push or infusion of three 50-mmol amps in 1 L D<sub class="calibre10">5</sub>W if less urgent</p>
<p class="noindent2">Can estimate mmol of HCO<sub class="calibre10">3</sub> needed as [desired-current HCO<sub class="calibre10">3</sub>]<sub class="calibre10">serum</sub> × wt (kg) × 0.4</p>
<p class="noindent2">Side effects: ↑ volume, ↑ Na, ↓ ICa, ↑ P<sub class="calibre10">a</sub>CO<sub class="calibre10">2</sub> (&amp; ∴ intracellular acidosis; ∴ <i class="calibre6">must ensure adequate ventilation</i> to blow off CO<sub class="calibre10">2</sub>)</p>
<p class="h1cr">M<small class="calibre31">ETABOLIC</small> A<small class="calibre31">LKALOSIS</small></p>
<p class="h">Pathophysiology <span class="r1">(</span><span class="r2">CJASN</span> <span class="r1">2020;15:1848)</span></p>
<p class="noindent1">• Saline-responsive etiologies require <i class="calibre6">initiating event</i> and <i class="calibre6">maintenance phase</i></p>
<p class="noindent1">• <i class="calibre6">Initiating event:</i> net HCO<sub class="calibre10">3</sub><sup class="calibre19">−</sup> reabsorption (due to loss of volume, Cl<sup class="calibre19">-</sup>, and/or K<sup class="calibre19">+</sup>) or loss of H<sup class="calibre19">+</sup></p>
<p class="noindent2"><b class="calibre7">Loss of H<sup class="calibre19">+</sup></b> (± Cl<sup class="calibre19">-</sup>) from GI tract, kidneys, or transcellular shift in hypokalemia</p>
<p class="noindent2"><b class="calibre7">Contraction alkalosis:</b> loss of HCO<sub class="calibre10">3</sub><sup class="calibre19">-</sup>-poor fluid → extracellular fluid “contracts” around fixed amount of HCO<sub class="calibre10">3</sub><sup class="calibre19">-</sup> → ↑ HCO<sub class="calibre10">3</sub><sup class="calibre19">-</sup> concentration</p>
<p class="noindent2"><b class="calibre7">Exogenous alkali:</b> iatrogenic HCO<sub class="calibre10">3</sub><sup class="calibre19">-</sup> (with renal impairment), milk-alkali syndrome</p>
<p class="noindent2"><b class="calibre7">Posthypercapnia:</b> resp. acidosis → compensation with H<sup class="calibre19">+</sup> excretion and HCO<sub class="calibre10">3</sub><sup class="calibre19">-</sup> retention; rapid correction of hypercapnia (eg, intubation) → transient excess HCO<sub class="calibre10">3</sub><sup class="calibre19">-</sup></p>
<p class="noindent1">• <i class="calibre6">Maintenance phase</i></p>
<p class="noindent2"><b class="calibre7">Volume depletion</b> → ↑ ATII → ↑ PCT reabsorption of HCO<sub class="calibre10">3</sub><sup class="calibre19">-</sup> &amp; ↑ aldosterone (see below)</p>
<p class="noindent2"><b class="calibre7">Cl<sup class="calibre19">-</sup> depletion</b> → ↓ Cl<sup class="calibre19">-</sup> uptake in macula densa → ↑ RAS &amp; ↑ CCD Cl<sup class="calibre19">-</sup>/HCO<sub class="calibre10">3</sub><sup class="calibre19">-</sup> exchanger</p>
<p class="noindent2"><b class="calibre7">Hypokalemia</b> → transcellular K<sup class="calibre19">+</sup>/H<sup class="calibre19">+</sup> exchange; intracellular acidosis → HCO<sub class="calibre10">3</sub><sup class="calibre19">-</sup> reabsorption and ammoniagenesis &amp; ↑ distal H<sup class="calibre19">+</sup>-K<sup class="calibre19">+</sup>-ATPase activity → HCO<sub class="calibre10">3</sub><sup class="calibre19">-</sup> retention</p>
<p class="noindent2"><b class="calibre7">Hyperaldosteronism</b> (1° or 2°) → ↑ CCD α-intercalated H<sup class="calibre19">+</sup> secretion w/ HCO<sub class="calibre10">3</sub><sup class="calibre19">-</sup> retention &amp; Na<sup class="calibre19">+</sup> reabsorption in principal cell → H<sup class="calibre19">+</sup> secretion (for electrical neutrality)</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><a id="page_4-5" class="calibre4"></a><p class="tbodyc"><b class="calibre7">Etiologies of Metabolic Alkalosis</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Saline responsive</b></p>
<p class="tbodyh">UCl &lt;25</p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">GI loss of H</b><sup class="calibre27">+</sup>: emesis, NGT suction, villous adenoma, chloridorrhea</p>
<p class="tbodyh"><b class="calibre7">Renal loss</b>: loop/thiazide, ↓ Cl intake, milk-alkali, Pendred syndrome</p>
<p class="tbodyh">Posthypercapnia, sweat losses in cystic fibrosis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Saline resistant</b></p>
<p class="tbodyh">UCl &gt;40</p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">Hypertensive</i> <b class="calibre7">(mineralocorticoid excess)</b></p>
<p class="tbodyh">1° hyperaldosteronism (eg, Conn’s)</p>
<p class="tbodyh">2° hyperaldosteronism (eg, renovascular dis., renin-secreting tumor)</p>
<p class="tbodyh">Non-aldo (Cushing’s, Liddle’s, exogenous mineralocorticoids, licorice)</p>
<p class="tbodyh"><i class="calibre6">Normotensive</i></p>
<p class="tbodyh">Severe hypokalemia (K&lt;2); exogenous alkali load (w/ AKI or ↓ vol)</p>
<p class="tbodyh">Bartter’s syndrome (loop-like); Gitelman’s syndrome (thiazide-like)</p></td>
</tr>
</tbody>
</table>
<p class="h">Workup</p>
<p class="noindent1">• Check <b class="calibre7">volume status</b> and <b class="calibre7">U<sub class="calibre10">Cl</sub></b></p>
<p class="noindent2">U<sub class="calibre10">Cl</sub> &lt;25 mEq/L → saline responsive</p>
<p class="noindent2">U<sub class="calibre10">Cl</sub> &gt;40 mEq/L → saline resistant (unless currently receiving diuretics)</p>
<p class="noindent2">(U<sub class="calibre10">Na</sub> unreliable determinant of volume status in alkalemia → ↑ HCO<sub class="calibre10">3</sub><sup class="calibre19">-</sup> excretion → ↑ Na excretion; negatively charged HCO<sub class="calibre10">3</sub><sup class="calibre19">-</sup> w/ Na<sup class="calibre19">+</sup> maintaining electrical neutrality)</p>
<p class="noindent2">If U<sub class="calibre10">Cl</sub> &gt;40 and volume replete, ✓ U<sub class="calibre10">K</sub>; U<sub class="calibre10">K</sub> &lt;20 laxative abuse; U<sub class="calibre10">K</sub> &gt;30, ✓ <b class="calibre7">blood pressure</b></p>
<div class="cap">
<p class="caption"><a id="fig4-3" class="calibre4"></a><b class="calibre7">Figure 4-3</b> Approach to metabolic alkalosis</p>
<p class="imagef1"><img src="../images/00064.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="h">Treatment of severe metabolic alkalosis (pH &gt;7.6) <span class="r1">(</span><span class="r2">JASN</span> <span class="r1">2012;23:204)</span></p>
<p class="noindent1">• If saline responsive: resuscitate with Cl-rich solution (NS), replete K, d/c diuretics cardiopulmonary disease precludes hydration, can use KCl, acetazolamide, HCl</p>
<p class="noindent1">• Hyperaldosteronism: treat underlying condition, K-sparing diuretic, resect adenoma if 1<sup class="calibre19">o</sup></p>
<p class="h1cr">R<small class="calibre31">ESPIRATORY</small> A<small class="calibre31">CIDOSIS</small> <span class="r3">(</span><span class="r4">NEJM</span> <span class="r3">1989;321:1223;</span> <span class="r4">Crit Care</span><span class="r3"> 2010;14:220)</span></p>
<p class="h">Etiologies <span class="r">(also see “Hypercapnia”; P<sub class="calibre10">a</sub>CO<sub class="calibre10">2</sub> = VCO<sub class="calibre10">2</sub>/V<sub class="calibre10">E</sub>(</span>1<span class="r">-V<sub class="calibre10">D</sub>/V<sub class="calibre10">T</sub>); V<sub class="calibre10">E</sub> = RR x V<sub class="calibre10">T</sub>)</span></p>
<p class="noindent1">• ↑<b class="calibre7"> CO<sub class="calibre10">2</sub> production</b> (↑ VCO<sub class="calibre10">2</sub>): fever, thyrotoxicosis, sepsis, steroids, overfeeding (carbs)</p>
<p class="noindent1">• <b class="calibre7">CNS depression</b> (↓ RR and/or V<sub class="calibre10">T</sub>): sedatives (opiates, benzos, etc.), CNS trauma, central sleep apnea, obesity, hypoventilation, hypothyroidism</p>
<p class="noindent1">• <b class="calibre7">Neuromuscular disorders</b> (↓ V<sub class="calibre10">T</sub>)<b class="calibre7">:</b> Guillain-Barré, poliomyelitis, ALS, MS, paralytics, myasthenia gravis, muscular dystrophy, severe ↓ P &amp; K, high spinal cord injury</p>
<p class="noindent1">• <b class="calibre7">Chest wall</b> (↓ V<sub class="calibre10">T</sub>): PTX, hemothorax, flail chest, kyphoscoliosis, ankylosing spondylitis</p>
<p class="noindent1">• <b class="calibre7">Upper airway</b> (↓ V<sub class="calibre10">T</sub>)<b class="calibre7">:</b> foreign body, laryngospasm, OSA, esophageal intubation</p>
<p class="noindent1">• <b class="calibre7">Lower airway (gas exchange)</b> (↑ V<sub class="calibre10">D</sub> and/or ↓ V<sub class="calibre10">T</sub>): asthma, COPD, pulm edema, IPF</p>
<p class="noindent2">Often hypoxia → ↑ RR → resp. alk., but muscle fatigue → resp. acid</p>
<p class="noindent1">• Post infusion of bicarbonate in acidemic Pt w/ limited ability to ↑ minute ventilation</p>
<p class="h1cr">R<small class="calibre31">ESPIRATORY</small> A<small class="calibre31">LKALOSIS</small></p>
<p class="h">Etiologies <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2002;347:43;</span> <span class="r2">Crit Care</span> <span class="r1">2010;14:220)</span></p>
<p class="noindent1">• <b class="calibre7">Hypoxia</b> → <b class="calibre7">hyperventilation:</b> pneumonia, CHF, PE, restrictive lung disease, anemia</p>
<p class="noindent1">• <b class="calibre7">Primary hyperventilation</b></p>
<p class="noindent2">CNS stimulation, pain, anxiety, trauma, stroke, CNS infection, pontine tumors</p>
<p class="noindent2">drugs: salicylates toxicity (early), β-agonists, progesterone, methylxanthines, nicotine</p>
<p class="noindent2">pregnancy, sepsis, hepatic failure, hyperthyroidism, fever</p>
<p class="noindent1">• <b class="calibre7">Pseudorespiratory alkalosis:</b> ↓ perfusion w/ preserved ventilation (eg, CPR, severe HoTN) → ↓ delivery of CO<sub class="calibre10">2</sub> to lungs for excretion; low P<sub class="calibre10">a</sub>CO<sub class="calibre10">2</sub> but ↑ tissue CO<sub class="calibre10">2</sub></p>
<h2 class="ct"><a id="h56" class="calibre8"></a><a id="page_4-6" class="calibre8"></a><a href="part0003.html#rh63" class="calibre8">SODIUM AND WATER HOMEOSTASIS</a></h2>
<p class="h1cr">O<small class="calibre31">VERVIEW</small></p>
<p class="h">General <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;372:55 &amp; 373:1350)</span></p>
<p class="noindent1">• Disorders of serum sodium are generally due to Δs in <i class="calibre6">total body water</i>, not sodium</p>
<p class="noindent1">• Hyper- or hypo-osmolality → rapid water shifts → Δs in brain cell volume → Δ MS, seizures</p>
<p class="h">Key hormones</p>
<p class="noindent1">• <b class="calibre7">Antidiuretic hormone (ADH):</b> primary hormone that regulates <i class="calibre6">sodium concentration</i></p>
<p class="noindent2"><i class="calibre6">Stimuli:</i> hyperosmolality (290–295 mOsm), ↓↓ effective arterial volume, angiotensin II</p>
<p class="noindent2"><i class="calibre6">Action:</i> insertion of aquaporin-2 channels in principal cells → passive water reabsorption</p>
<p class="noindent2"><b class="calibre7">urine osmolality</b> is an indirect functional assay of the ADH-renal axis</p>
<p class="noindent2">U<sub class="calibre10">osm</sub> range: 50 mOsm/L (no ADH) to 1200 mOsm/L (maximal ADH)</p>
<p class="noindent1">• <b class="calibre7">Aldosterone:</b> primary hormone that regulates <i class="calibre6">total body sodium</i> (and ∴ volume)</p>
<p class="noindent2"><i class="calibre6">Stimuli for secretion:</i> hypovolemia (via renin and angiotensin II), hyperkalemia</p>
<p class="noindent2"><i class="calibre6">Action:</i> iso-osmotic principal cell reabsorption of Na via epithelial Na channel (ENaC) in exchange for K<sup class="calibre19">+</sup> or H<sup class="calibre19">+</sup></p>
<p class="h1cr">H<small class="calibre31">YPONATREMIA</small></p>
<p class="h">Pathophysiology <span class="r1">(</span><span class="r2">JASN</span><span class="r1"> 2008;19:1076;</span> <span class="r2">NEJM</span><span class="r1"> 2015;372:1349)</span></p>
<p class="noindent1">• <b class="calibre7">Excess H<sub class="calibre10">2</sub>O relative to Na</b>, usually due to ↑ <b class="calibre7">ADH</b></p>
<p class="noindent1">• ↑ ADH may be <i class="calibre6">appropriate</i> (eg, hypovolemia or hypervolemia with ↓ EAV)</p>
<p class="noindent1">• ↑ ADH may be <i class="calibre6">inappropriate</i> (SIADH)</p>
<p class="noindent1">• Rarely, ↓ ADH (appropriately suppressed), but kidneys unable to maintain nl [Na]<sub class="calibre10">serum</sub></p>
<p class="noindent2">at steady state, solute intake = solute excretion; urine output = solute excretion/U<sub class="calibre10">osm</sub></p>
<p class="noindent2">nl dietary solute load ~750 mOsm/d, min U<sub class="calibre10">osm</sub> = 50 mOsm/L, ∴ UOP can be up to ~15 L</p>
<p class="noindent2">↑ <i class="calibre6">H<sub class="calibre10">2</sub>O intake (1</i>° <i class="calibre6">polydipsia):</i> ingestion of massive quantities (usually &gt;15 L/d) of free H<sub class="calibre10">2</sub>O overwhelms diluting ability of kidney → H<sub class="calibre10">2</sub>O retention</p>
<p class="noindent2">↓ solute intake (“tea &amp; toast” &amp; beer potomania<i class="calibre6">):</i> ↓↓ daily solute load → insufficient solute to excrete H<sub class="calibre10">2</sub>O intake (eg, if only 250 mOsm/d, minimum U<sub class="calibre10">osm</sub> = 50 mOsm/L → excrete in ~5 L; if H<sub class="calibre10">2</sub>O ingestion exceeds this amount → H<sub class="calibre10">2</sub>O retention)</p>
<p class="h">Workup <span class="r1">(</span><span class="r2">JASN</span> <span class="r1">2012;23:1140 &amp; 2017;28:1340;</span> <span class="r2">Crit Care</span> <span class="r1">2013;17:206;</span> <span class="r2">NEJM</span> <span class="r1">2015;372:55)</span></p>
<p class="noindent1">• <b class="calibre7">History:</b> (1) acute vs. chronic (&gt;48 h); (2) sx severity; (3) risk for neuro complications (alcoholism, malnourished, cirrhosis, older women on thiazides, hypoxia, hypoK)</p>
<p class="noindent1">• Measure <b class="calibre7">plasma osmolality</b></p>
<p class="noindent2"><i class="calibre6">Hypotonic (P<sub class="calibre10">osm</sub></i> &lt;<i class="calibre6">280)</i> most common scenario; true excess of free H<sub class="calibre10">2</sub>O relative to Na</p>
<p class="noindent2"><i class="calibre6">Isotonic (P<sub class="calibre10">osm</sub> 280</i>–<i class="calibre6">295):</i> rare lab artifact from hyperlipidemia or hyperproteinemia</p>
<p class="noindent2"><i class="calibre6">Hypertonic (P<sub class="calibre10">osm</sub></i> &gt;<i class="calibre6">295):</i> excess of another effective osmole (eg, glucose, mannitol) that draws H<sub class="calibre10">2</sub>O intravascularly; for each 100 mg/dL ↑ glc &gt;100 mg/dL → ↓ [Na] by ~2 mEq/L</p>
<p class="noindent1">• For hypotonic hyponatremia, ✓ <b class="calibre7">volume status</b> (JVP, skin turgor, dry axilla, mucous membranes, edema, ascites), effusions, vital signs, orthostatics, BUN/Cr, FE<sub class="calibre10">UricAcid</sub>, U<sub class="calibre10">Na</sub></p>
<p class="noindent1">• Measure <b class="calibre7">U<sub class="calibre10">osm</sub></b>, although useful for dx in limited circumstances, b/c almost always &gt;300</p>
<p class="noindent2">U<sub class="calibre10">osm</sub> &lt;100 in ↑ H<sub class="calibre10">2</sub>O intake (1<sup class="calibre19">o</sup> polydipsia) or ↓ solute intake (beer potomania, “tea &amp; toast”)</p>
<p class="noindent2">U<sub class="calibre10">osm</sub> &gt;300 does not mean SIADH; must determine if ↑ ADH appropriate or inappropriate</p>
<p class="noindent2">however, U<sub class="calibre10">osm</sub> can be important when deciding on <i class="calibre6">treatment</i> (see below)</p>
<p class="noindent1">• If euvolemic and ↑ U<sub class="calibre10">osm</sub>, evaluate for glucocorticoid insufficiency and hypothyroidism</p>
<p class="noindent1">• If available, consider FE<sub class="calibre10">UricAcid</sub> as &gt;12% suggests SIADH <span class="r1">(</span><span class="r2">J Clinc Endo</span> <span class="r1">2008;93:2991)</span></p>
<div class="cap">
<p class="caption"><a id="fig4-4" class="calibre4"></a><b class="calibre7">Figure 4-4</b> Approach to hyponatremia</p>
<p class="imagef1"><img src="../images/00065.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="h"><a id="page_4-7" class="calibre4"></a>Hypovolemic hypotonic hyponatremia <span class="r">(ie,</span> ↓↓<span class="r"> total body Na,</span> ↓<span class="r"> TBW)</span></p>
<p class="noindent1">• <b class="calibre7">Renal losses</b> (U<sub class="calibre10">Na</sub> &gt;20 mEq/L, FE<sub class="calibre10">Na</sub> &gt;1%): diuretics (esp. thiazides, because loop diuretics</p>
<p class="noindent2">↓ tonicity of medullary interstitium, Δ for H<sub class="calibre10">2</sub>O absorption, &amp; ∴ urine concentrating ability), salt-wasting nephropathy, cerebral salt wasting, mineralocorticoid deficiency</p>
<p class="noindent1">• <b class="calibre7">Extrarenal losses</b> (U<sub class="calibre10">Na</sub> &lt;10 mEq/L, U<sub class="calibre10">Cl</sub> &lt;10 mEq/L if alkalemia, FE<sub class="calibre10">Na</sub> &lt;1%): hemorrhage, GI loss (diarrhea or vomiting), third-spacing (pancreatitis), ↓ PO intake, insensible losses</p>
<p class="h">Euvolemic hypotonic hyponatremia <span class="r">(ie,</span> ↑<span class="r"> TBW relative to total body Na)</span></p>
<p class="noindent1">• <b class="calibre7">SIADH</b> (euvolemia or mild hypervolemia, typically <b class="calibre7">inapprop U<sub class="calibre10">osm</sub></b> &gt;<b class="calibre7">100,</b> U<sub class="calibre10">Na</sub> &gt;20 mEq/L)</p>
<p class="noindent2"><b class="calibre7">Malignancy:</b> lung (SCLC), brain, GI, GU, lymphoma, leukemia, thymoma, mesothelioma</p>
<p class="noindent2"><b class="calibre7">Pulmonary:</b> pneumonia, TB, aspergillosis, asthma, COPD, PTX, mechanical ventilation</p>
<p class="noindent2"><b class="calibre7">Intracranial:</b> trauma, stroke, SAH, seizure, infxn, hydrocephalus, Guillain-Barré</p>
<p class="noindent2"><b class="calibre7">Drugs:</b> antipsychotics, antidepress. (SSRI, TCA, MAOi), haloperidol, chemo (vincristine, cisplatin), AVP, MDMA, NSAIDs, opiates, amiodarone <span class="r1">(</span><span class="r2">Am J Kidney Dis</span> <span class="r1">2008;52:144)</span></p>
<p class="noindent2"><b class="calibre7">Miscellaneous:</b> pain, nausea, postoperative state</p>
<p class="noindent1">• <b class="calibre7">Endocrinopathies:</b> ↑ ADH activity seen in <i class="calibre6">glucocorticoid deficiency</i> (co-secretion of ADH &amp; CRH) and <i class="calibre6">severe hypothyroidism/myxedema coma</i> (↓ CO/SVR → ADH release &amp; ↓ GFR)</p>
<p class="noindent1">• <b class="calibre7">Psychogenic polydipsia</b> (U<sub class="calibre10">osm</sub> &lt;100, ↓ FE<sub class="calibre10">Uric Acid</sub>): usually intake &gt;15 L/d</p>
<p class="noindent1">• <b class="calibre7">Low solute</b> (↓ U<sub class="calibre10">Na</sub>, ↓ U<sub class="calibre10">osm</sub>) “tea &amp; toast”; beer potomania</p>
<p class="noindent1">• Reset osmostat: chronic malnutrition (↓ intracellular osmoles) or pregnancy (hormonal</p>
<p class="noindent2">effects) → ADH physiology reset to regulate a lower [Na]<sub class="calibre10">serum</sub></p>
<p class="h">Hypervolemic hypotonic hyponatremia <span class="r">(ie,</span> ↑<span class="r"> total body Na,</span> ↑ ↑<span class="r"> TBW)</span></p>
<p class="noindent1">• ↓ EAV → ↑ RAAS → ↑ aldosterone &amp; ↑ adrenergic tone → ↑↑ ADH <span class="r1">(</span><span class="r2">Am J Med</span> <span class="r1">2013;126:S1)</span></p>
<p class="noindent1">• <b class="calibre7">CHF</b> (↓ CO &amp; renal venous congestion → ↓ EAV; U<sub class="calibre10">Na</sub> &lt;10 mEq/L, FE<sub class="calibre10">Na</sub> &lt;1%)</p>
<p class="noindent1">• <b class="calibre7">Cirrhosis</b> (splanchnic arterial vasodilation + ascites → ↓ EAV; U<sub class="calibre10">Na</sub> &lt;10 mEq/L, FE<sub class="calibre10">Na</sub> &lt;1%)</p>
<p class="noindent1">• <b class="calibre7">Nephrotic syndrome</b> (hypoalbuminemia → edema → ↓ EAV; U<sub class="calibre10">Na</sub> &lt;10 mEq/L, FE<sub class="calibre10">Na</sub> &lt;1%)</p>
<p class="noindent1">• <b class="calibre7">Advanced renal failure</b> (diminished ability to excrete free H<sub class="calibre10">2</sub>O; U<sub class="calibre10">Na</sub> &gt;20 mEq/L)</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;372:55;</span> <span class="r2">JASN</span> <span class="r1">2017;28:1340;</span> <span class="r2">CJASN</span> <span class="r1">2018;13:641 &amp; 984)</span></p>
<p class="noindent1">• <b class="calibre7">Approach:</b> depends on <i class="calibre6">volume status</i>, <i class="calibre6">acuity</i> of hyponatremia, and if <i class="calibre6">symptomatic</i></p>
<p class="noindent2">Acute sx: <i class="calibre6">initial</i> rapid correction of [Na]<sub class="calibre10">serum</sub> (2 mEq/L/h for the first 2–3 h) until sx resolve</p>
<p class="noindent2">Asx or chronic symptomatic: correct [Na]<sub class="calibre10">serum</sub> at rate of ≤0.5 mEq/L/h</p>
<p class="noindent2">Rate ↑ Na <i class="calibre6">should not exceed 6</i> (chronic) to <i class="calibre6">8</i> (acute) mEq/L/d to avoid central pontine myelinolysis/osmotic demyelination (CPM/ODS: paraplegia, dysarthria, dysphagia)</p>
<p class="noindent2">If severe (&lt;120) or neuro sx: consider 3% NaCl. dDAVP 1-2 µg q8h in consultation with nephrology (to prevent rapid overcorrection) <span class="r1">(</span><span class="r2">AJKD</span> <span class="r1">2013;61:571;</span> <span class="r2">CJASN</span> <span class="r1">2018; 13:641)</span></p>
<p class="noindent1">• <b class="calibre7">Frequent lab draws</b> and <b class="calibre7">IVF rate adjustments</b> are cornerstones of treatment</p>
<p class="noindent1">• <b class="calibre7">Rapid correction:</b> can lead to CPM/ODS (esp if chronic or Na &lt;120 mEq/L). Should be emergently reversed w/ dDAVP ± D<sub class="calibre10">5</sub>W; partial neuro recovery possible <span class="r1">(</span><span class="r2">CJASN</span> <span class="r1">2014;9:229)</span>.</p>
<p class="noindent1">• <b class="calibre7">Effect of IV fluids</b>: complex as depends not only on [Na]<sub class="calibre10">infusate</sub> but also UOP and U<sub class="calibre10">osm</sub></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre20"/>
<col class="calibre21"/>
</colgroup>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Scenario</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Formula to estimate new [Na]<sub class="calibre17">serum</sub> after 1 L infusion</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">If minimal UOP and none of infused Na excreted</p></td>
<td class="th1"><p class="tbodyc"><img src="../images/00066.jpeg" alt="" class="calibre5"/></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">If euvolemic (eg, in SIADH) &amp; all infused Na excreted</p></td>
<td class="th1"><p class="tbodyc"><img src="../images/00067.jpeg" alt="" class="calibre5"/></p></td>
</tr>
</tbody>
</table>
<p class="noindentx">In SIADH “fixed” high U<sub class="calibre10">osm</sub>. ∴ in SIADH w/ U<sub class="calibre10">osm</sub> 616, 1 L NS (154 mEq Na or 308 mOsm solute in 1 L H<sub class="calibre10">2</sub>O) will be excreted in 0.5 L H<sub class="calibre10">2</sub>O → net<i class="calibre6"> gain</i> 0.5 L H<sub class="calibre10">2</sub>O. ∴ NS <i class="calibre6">worsens</i> [Na]<sub class="calibre10">serum</sub> if U<sub class="calibre10">osm</sub> &gt;infusate<sub class="calibre10">osm</sub>. In contrast, 1 L 3% NaCl (1026 mOsm) would be excreted in ~1.7 L urine → net<i class="calibre6"> loss</i> 0.7 L H<sub class="calibre10">2</sub>O. ∴ 3% saline ↑ [Na]<sub class="calibre10">serum</sub>.</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre23"/>
<col class="calibre23"/>
<col class="calibre23"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="4"><p class="tbodyc"><b class="calibre7">Effect of 1 L infusion in 70-kg male w/ [Na]<sub class="calibre17">serum</sub> 110 mEq/L &amp; U<sub class="calibre17">osm</sub> 616 mOsm/kg</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">IVF Type</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">[Na]<sub class="calibre17">content</sub></b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">No UOP</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Infused Na excreted</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">0.9% NaCl</p></td>
<td class="th1"><p class="tbodyc">154 mEq/L</p></td>
<td class="th1"><p class="tbodyc">+1.0 mEq/L</p></td>
<td class="th1"><p class="tbodyc">-1.3 mEq/L</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">3% NaCl</p></td>
<td class="th1"><p class="tbodyc">513 mEq/L</p></td>
<td class="th1"><p class="tbodyc">+9.4 mEq/L</p></td>
<td class="th1"><p class="tbodyc">+1.8 mEq/L</p></td>
</tr>
</tbody>
</table>
<p class="noindent1">• <b class="calibre7">Hypovolemic hyponatremia:</b> volume repletion with isotonic 0.9% saline at a <b class="calibre7">slow rate</b>. Once volume replete → stimulus for ADH removed (w/ very short ADH t<sub class="calibre10">½</sub>) → kidneys excrete free H<sub class="calibre10">2</sub>O → serum Na will correct rapidly (D<sub class="calibre10">5</sub>W ± dDAVP if overcorrection)</p>
<p class="noindent1">• <b class="calibre7">SIADH</b> <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2007;356:2064;</span> <span class="r2">AJKD</span><span class="r1"> 2020;76:203)</span>: <b class="calibre7">fluid restrict</b> + treat underlying cause</p>
<p class="noindent2"><b class="calibre7">hypertonic saline</b> (± loop diuretic; <span class="r2">AJKD</span><span class="r1"> 2020;76:203</span>) if sx or Na fails to ↑ w/ fluid restriction Intermittent bolus of 3% saline (~2 mL/kg q6h) vs. continuous infusion (~0.5 mL/kg/h) similar <span class="r1">(</span><span class="r2">JAMA IM</span> <span class="r1">2021;181:81)</span> when moderate symptoms. Must recheck serum Na frequently during hypertonic use (at least q2h).</p>
<p class="noindent2"><a id="page_4-8" class="calibre4"></a>NaCl tabs if chronic and no CHF. Consider urea 0.25–0.5 g/kg/d <span class="r1">(</span><span class="r2">CJASN</span> <span class="r1">2018;13:1627)</span></p>
<p class="noindent2">aquaresis: vaptans (vasopressin receptor antag) for refractory SIADH <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;372:23)</span></p>
<p class="noindent1">• <b class="calibre7">Hypervolemic hyponatremia:</b> free water restrict (1<sup class="calibre19">st</sup> line), diurese w/ loop diuretics (avoid thiazides) &amp; ↑ EAV (vasodilators to ↑ CO in CHF, colloid infusion in cirrhosis)</p>
<p class="noindent2">vaptans sometimes used; however, no mortality benefit, hypoNa recurs after stopping drug, high risk of overcorrection, contraindicated in cirrhosis <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;372:2207)</span></p>
<p class="h1cr">H<small class="calibre31">YPERNATREMIA</small></p>
<p class="h">Pathophysiology <span class="r1">(</span><span class="r2">Crit Care</span> <span class="r1">2013;17:206;</span> <span class="r2">NEJM</span> <span class="r1">2015;372:55)</span></p>
<p class="noindent1">• Deficit of water relative to sodium; by definition, all hypernatremic Pts are hypertonic</p>
<p class="noindent1">• Usually <b class="calibre7">loss of hypotonic fluid</b> (ie, “dehydration”); occasionally infusion of hypertonic fluid, post-ATN diuresis w/ loss of low or electrolyte-free water <span class="r1">(</span><span class="r2">Am J Neph</span> <span class="r1">2012;36:97)</span></p>
<p class="noindent1">• <b class="calibre7"><i class="calibre6">And</i> impaired access to free water</b> (eg, intubation, Δ MS, elderly): hypernatremia is a powerful thirst stimulus, ∴ usually only develops in Pts w/o access to H<sub class="calibre10">2</sub>O or ill</p>
<p class="h">Workup</p>
<p class="noindent1">• ✓ U<sub class="calibre10">osm</sub>, U<sub class="calibre10">Na</sub>, volume status (vital signs, orthostatics, JVP, skin turgor, BUN, Cr)</p>
<div class="cap">
<p class="caption"><a id="fig4-5" class="calibre4"></a><b class="calibre7">Figure 4-5</b> Approach to hypernatremia</p>
<p class="imagef1"><img src="../images/00068.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="h">Extrarenal H<sub class="calibre10">2</sub>O loss <span class="r">(U<sub class="calibre10">osm</sub></span> &gt;<span class="r">700–800)</span></p>
<p class="noindent1">• <b class="calibre7">GI H<sub class="calibre10">2</sub>O loss:</b> vomiting, NGT drainage, osmotic diarrhea, fistula, lactulose, malabsorption</p>
<p class="noindent1">• <b class="calibre7">Insensible loss:</b> fever, exercise, ventilation, burns</p>
<p class="h">Renal H<sub class="calibre10">2</sub>O loss <span class="r">(U<sub class="calibre10">osm</sub></span> &lt;<span class="r">700–800)</span></p>
<p class="noindent1">• <b class="calibre7">Diuresis:</b> osmotic (glucose, mannitol, urea), loop diuretics</p>
<p class="noindent1">• <b class="calibre7">Diabetes insipidus</b> <span class="r1">(</span><span class="r2">Nature Reviews Nephrology</span> <span class="r1">2015;11:576)</span></p>
<p class="noindent2">ADH deficiency (central) or resistance (nephrogenic)</p>
<p class="noindent2"><b class="calibre7">Central:</b> hypothalamic or posterior pituitary disease (congenital, trauma/surgery, infiltrative/IgG4); also idiopathic, hypoxic/ischemic encephalopathy (shock, Sheehan’s syndrome), anorexia, sarcoidosis, histiocytosis, drugs: EtOH, phenytoin, snake venom, tumors: craniopharyngioma, germinoma, lymphoma, leukemia, meningioma, pituitary</p>
<p class="noindent2"><b class="calibre7">Nephrogenic</b> <span class="r1">(</span><span class="r2">Annals</span> <span class="r1">2006;144:186)</span></p>
<p class="noindent2">congenital (ADH receptor V2 mutation, aquaporin-2 mutation; <span class="r2">Pediatric Clinics</span> <span class="r1">2019;66:227</span>)</p>
<p class="noindent2">drugs: <b class="calibre7">lithium</b>, amphotericin, demeclocycline, foscarnet, cidofovir, ifosfamide</p>
<p class="noindent2">metabolic: <b class="calibre7">hypercalcemia</b>, <b class="calibre7">severe hypokalemia</b>, protein malnutrition, congenital</p>
<p class="noindent2">tubulointerstitial: <b class="calibre7">postobstruction</b>, <b class="calibre7">recovery phase of ATN</b>, PKD, sickle cell, Sjögren’s, amyloid, pregnancy (placental vasopressinase)</p>
<p class="noindent2">DI usually presents as severe polyuria and mild hypernatremia</p>
<p class="h">Other <span class="r">(U<sub class="calibre10">osm</sub></span> &gt;<span class="r">700–800)</span></p>
<p class="noindent1">• <b class="calibre7">Na overload:</b> hypertonic saline (eg, resuscitation w/ NaHCO<sub class="calibre10">3</sub>), mineralocorticoid excess</p>
<p class="noindent1">• <b class="calibre7">Seizures</b>, ↑ <b class="calibre7">exercise:</b> ↑ intracellular osmoles → H<sub class="calibre10">2</sub>O shifts → transient ↑ [Na]<sub class="calibre10">serum</sub></p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;372:55)</span></p>
<p class="noindent1">• <b class="calibre7">Restore access to H<sub class="calibre10">2</sub>O</b> or supply daily requirement of H<sub class="calibre10">2</sub>O (≥1 L/d)</p>
<p class="noindent1">• <b class="calibre7">Replace free H<sub class="calibre10">2</sub>O deficit</b> (also replace concurrent volume deficit if appropriate):</p>
<p class="image1"><img src="../images/00069.jpeg" alt="" class="calibre5"/></p>
<p class="noindent2"><a id="page_4-9" class="calibre4"></a>eg, 1 L D<sub class="calibre10">5</sub>W given to 70-kg man w/ [Na] = 160 mEq/L will ↓ [Na]<sub class="calibre10">serum</sub> by 3.7 mEq</p>
<p class="noindent2">nb, do not forget to correct Na if hyperglycemia also present</p>
<p class="noindent1">• Rate of correction depends on acuity of onset and risk:</p>
<p class="noindent2">chronic (&gt;48 hr): ~12 mEq/d appears safe w/o risk of cerebral edema <span class="r1">(</span><span class="r2">CJASN</span><span class="r1"> 2019;14:656)</span></p>
<p class="noindent2">acute (&lt;48 hr): may ↓ Na by 2 mEq/L/h until Na 145</p>
<p class="noindent2">hyperacute (min-hrs) &amp; life threatening (ICH, seizure): rapidly infuse D<sub class="calibre10">5</sub>W ± emergent HD</p>
<p class="noindent1">• <i class="calibre6">Estimate:</i> in 70-kg man, 125 mL/h of free H<sub class="calibre10">2</sub>O will ↓ [Na] by ~0.5 mEq/L/h</p>
<p class="noindent1">• ½ NS (77 mEq/L) or ¼ NS (38 mEq/L) provides both volume &amp; free H<sub class="calibre10">2</sub>O (500 or 750 mL of free H<sub class="calibre10">2</sub>O per L, respectively); can give free H<sub class="calibre10">2</sub>O via NGT/OGT</p>
<p class="noindent1">• Formulas provide only estimates; ∴ recheck serum Na frequently</p>
<p class="noindent1">• <b class="calibre7">DI and osmotic diuresis:</b> see “Polyuria” section below</p>
<p class="noindent1">• <b class="calibre7">Na overload:</b> D<sub class="calibre10">5</sub>W + diuretic. Consider HD if life threatening (ICH, hypertonia, seizures).</p>
<p class="h1cr">P<small class="calibre31">OLYURIA</small></p>
<p class="h">Definition and pathophysiology</p>
<p class="noindent1">• <b class="calibre7">Polyuria</b> defined as &gt;3 L UOP per day</p>
<p class="noindent1">• Due to an <i class="calibre6">osmotic</i> or a <i class="calibre6">water diuresis;</i> almost always due to osmotic diuresis in inpatients</p>
<p class="h">Workup</p>
<p class="noindent1">• Perform a timed urine collection (6 h sufficient) and measure U<sub class="calibre10">osm</sub></p>
<p class="noindent1">• 24-h osmole excretion rate = 24-h UOP (actual or estimate) × U<sub class="calibre10">osm</sub></p>
<p class="noindent2">&gt;1000 mOsm/d → osmotic diuresis; &lt;800 mOsm/d → water diuresis</p>
<p class="h">Osmotic diuresis</p>
<p class="noindent1">• Etiologies</p>
<p class="noindent2">Hyperglycemia (&gt;180 exceeds PCT reabsorption), mannitol, propylene glycol</p>
<p class="noindent2">Na: NaCl IVF, recovering AKI (eg, post obstruction)</p>
<p class="noindent2">Urea: ↑ protein feeds, hypercatabolism (burns, steroids), GI bleed, resolving azotemia</p>
<p class="h">Water diuresis</p>
<p class="noindent1">• Etiologies: DI (Na<sub class="calibre10">serum</sub> &gt;143) or <b class="calibre7">1</b>° <b class="calibre7">polydipsia</b> (Na<sub class="calibre10">serum</sub> &lt;136)</p>
<p class="noindent2">see “Hypernatremia” above for list of causes of central and nephrogenic DI</p>
<p class="noindent1">• Workup of DI: U<sub class="calibre10">osm</sub> &lt;300 (complete) or 300–600 (partial)</p>
<p class="noindent2">water deprivation test (rarely used)</p>
<p class="noindent2">hypertonic saline-stimulated plasma copeptin &gt;4.9 pmoL/L indicates 1° polydipsia (97% accuracy vs. 77% for water deprivation; <span class="r2">NEJM</span><span class="r1"> 2018;379:428</span>)</p>
<div class="cap">
<p class="caption"><a id="fig4-6" class="calibre4"></a><b class="calibre7">Figure 4-6</b> Approach to polyuria</p>
<p class="imagef1"><img src="../images/00070.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="h">Treatment</p>
<p class="noindent1">• <b class="calibre7">1° polydipsia:</b> treat psychiatric illness, check meds, restrict access to free H<sub class="calibre10">2</sub>O</p>
<p class="noindent1">• <b class="calibre7">Osmotic diuresis:</b> address underlying cause, replace free H<sub class="calibre10">2</sub>O deficit (see “Hypernatremia” for formula to calculate) and ongoing losses</p>
<p class="noindent1">• <b class="calibre7">DI:</b></p>
<p class="noindent2">Central DI: desmopressin (dDAVP, 1<sup class="calibre19">st</sup> line), low Na/protein diet + HCTZ, chlorpropamide</p>
<p class="noindent2">Nephrogenic DI: treat underlying cause if possible; Na restriction + HCTZ (mild volume depletion → ↓ delivery of filtrate for free H<sub class="calibre10">2</sub>O absorption), consider amiloride for Li- induced DI <span class="r1">(</span><span class="r2">Kid Int</span> <span class="r1">2009;76:44)</span>, indomethacin <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">1991;324:850)</span> or trial desmopression</p>
<p class="noindent2">Pregnancy-induced DI: due to vasopressinase from placenta, ∴ Rx w/ dDAVP</p>
<h2 class="ct"><a id="h57" class="calibre8"></a><a id="page_4-10" class="calibre8"></a><a href="part0003.html#rh64" class="calibre8">POTASSIUM HOMEOSTASIS</a></h2>
<p class="h">Overview <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;373:60)</span></p>
<p class="noindent1">• Renal: K excretion regulated at <b class="calibre7">distal nephron</b> (CCD) by principal &amp; α-intercalated cells</p>
<p class="noindent2">Distal Na delivery &amp; urine flow: Na absorption → lumen electronegative → K secretion</p>
<p class="noindent2">Metabolic alkalemia and aldosterone: increase Na absorption and K secretion</p>
<p class="noindent2">nb, diurnal urinary K excretion (day &gt;night), ∴ 24-h sample preferred over spot</p>
<p class="noindent1">• Transcellular shifts: most common cause of acute ∆ in serum K (98% intracellular)</p>
<p class="noindent2">Acid-base disturbance: K<sup class="calibre19">+</sup>/H<sup class="calibre19">+</sup> exchange across cell membranes</p>
<p class="noindent2">Insulin → stimulates Na-K ATPase → hypokalemia (mitigates postprandial ↑ K)</p>
<p class="noindent2">Catecholamines → stimulate Na-K ATPase → hypokalemia; reversed by β-blockers</p>
<p class="noindent2">Massive necrosis (eg, tumor lysis, rhabdo, ischemic bowel) → release of intracellular K</p>
<p class="noindent2">Hypo- or hyperkalemic periodic paralysis: rare disorders due to channel mutations</p>
<p class="noindent1">• Diet: alone rarely causes ↑ or ↓ K (total body store ~3500 mEq, daily intake ~100 mEq)</p>
<p class="h1cr">H<small class="calibre31">YPOKALEMIA</small></p>
<p class="h">Transcellular shifts <span class="r">(U<sub class="calibre10">K:Cr</sub></span> &lt;1<span class="r">3 mEq/g)</span></p>
<p class="noindent1">• Alkalemia, insulin, catecholamines, β<sub class="calibre10">2</sub>-agonists, hypothermia, hypokalemic/thyrotoxic periodic paralysis, acute ↑ hematopoiesis (megaloblastic anemia Rx w/ B<sub class="calibre10">12</sub>, AML crisis), chloroquine; overdose: Ba/Cs, antipsychotics (risperidone, quetiapine), theophylline</p>
<p class="h">GI potassium losses <span class="r">(U<sub class="calibre10">K:Cr</sub></span> &lt;1<span class="r">3 mEq/g)</span></p>
<p class="noindent1">• GI losses <i class="calibre6">plus</i> metabolic acidosis: diarrhea, laxative abuse, villous adenoma</p>
<p class="noindent1">• Vomiting &amp; NGT drainage usually manifest as <i class="calibre6">renal losses</i> due to 2° hyperaldo &amp; met. alk.</p>
<p class="h">Renal potassium losses <span class="r">(U<sub class="calibre10">K:Cr</sub></span> &gt;1<span class="r">3 mEq/g)</span></p>
<p class="noindent1">• Hypotensive or normotensive</p>
<p class="noindent2">acidosis: DKA, RTA [distal RTAs (type I) &gt;proximal RTAs (type II)]</p>
<p class="noindent2">alkalosis: diuretics (thiazide &gt;loop), vomiting/NGT drainage (via 2° hyperaldosteronism)</p>
<p class="noindent3">Bartter’s syndrome (loop of Henle dysfxn→ furosemide-like effect; <span class="r2">JASN</span> <span class="r1">2017;28:2540</span>)</p>
<p class="noindent3">Gitelman’s syndrome (DCT dysfxn→ thiazide-like effect <span class="r1">(</span><span class="r2">KI</span> <span class="r1">2017;91:24)</span></p>
<p class="noindent2">drugs: acetaminophen overdose, PCN, gent., ampho, foscarnet, cisplatin, ifosfamide</p>
<p class="noindent2">↓ Mg: less Mg to inhibit principal cell ROMK channel, ∴ ↑ K secretion <span class="r1">(</span><span class="r2">JASN</span> <span class="r1">2010;21:2109)</span></p>
<p class="noindent1">• Hypertensive: mineralocorticoid excess</p>
<p class="noindent2">1° hyperaldosteronism (eg, Conn’s syndrome, glucocorticoid-remediable aldosteronism)</p>
<p class="noindent2">2° hyperaldosteronism (eg, renovascular disease, renin-secreting tumor)</p>
<p class="noindent2">Nonaldosterone mineralocorticoid (eg, Cushing’s, Liddle’s [↑ ENaC], exogenous, licorice)</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Nausea, vomiting, ileus, weakness, muscle cramps, rhabdomyolysis, ↓ insulin secretion</p>
<p class="noindent1">• Renal: ammoniagenesis, phosphaturia, hypocitraturia, NaCl &amp; HCO<sub class="calibre10">3</sub> retention, polyuria</p>
<p class="noindent1">• ECG: may see U waves, ↑ QT, flat Tw, ST depression, ventricular ectopy (PVCs, VT, VF)</p>
<p class="h">Workup <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2021;12:1216)</span></p>
<p class="noindent1">• Identify transcellular shifts &amp; treat. TTKG validity questioned <span class="r1">(</span><span class="r2">Curr Op Nephro</span> <span class="r1">2011;20:547)</span>.</p>
<p class="noindent1">• ✓ <b class="calibre7">U<sub class="calibre10">K:Cr</sub></b>: &gt;13 mEq/g → renal loss; &lt;13 mEq/g → extrarenal loss <span class="r1">(</span><span class="r2">AJKD</span> <span class="r1">2019;74:682)</span></p>
<p class="noindent1">• If renal losses, ✓ <b class="calibre7">BP</b>, <b class="calibre7">acid-base</b>, <b class="calibre7">U<sub class="calibre10">Cl</sub></b> (U<sub class="calibre10">Na</sub> unreliable), U<sub class="calibre10">Ca/Cr</sub>, renin, aldosterone, cortisol</p>
<div class="cap">
<p class="caption"><a id="fig4-7" class="calibre4"></a><b class="calibre7">Figure 4-7</b> Approach to hypokalemia</p>
<p class="imagef1"><img src="../images/00071.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="h"><a id="page_4-11" class="calibre4"></a>Treatment <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2000;160:2429)</span></p>
<p class="noindent1">• <i class="calibre6">If true potassium deficit:</i> <b class="calibre7">potassium repletion</b> (↓ 1 mEq/L ≈ 200 mEq total body loss)</p>
<p class="noindent2">Dosage: 40 mEq PO q4h, 10 mEq/h (IV), 20 mEq/h (central line), 40 mEq in 1 L IVF</p>
<p class="noindent1">• Replete K<sup class="calibre19">+</sup> to &gt;3 or &gt;4 mEq/L if high-risk (HTN, CHF, arrhythmias, MI, digoxin, cirrhosis)</p>
<p class="noindent1">• Beware of excessive potassium repletion if transcellular shift cause of hypokalemia</p>
<p class="noindent1">• Treat underlying cause (if ↓ vol: avoid dextrose as ↑ insulin → intracellular potassium shifts)</p>
<p class="noindent1">• Consider Rx that ↓ K loss: ACEI/ARB, K<sup class="calibre19">+</sup>-sparing diuretics, βB</p>
<p class="noindent1">• Replete Mg if &lt;2 mEq/L: IV Mg-SO<sub class="calibre10">4</sub> 1–2 g q2h and oral Mg-oxide (limited by diarrhea).</p>
<p class="noindent2">Causes of low Mg: GI loss (diarrhea, bypass, pancreatitis, malnutrition, PPI); renal loss (diuretics, nephrotoxic drugs, EtOH, ↑ Ca, 1° wasting syndromes, volume expansion)</p>
<p class="h1cr">H<small class="calibre31">YPERKALEMIA</small></p>
<p class="h">Transcellular shifts <span class="r1">(</span><span class="r2">BMJ</span> <span class="r1">2009;339:1019)</span></p>
<p class="noindent1">• Acidemia, ↓ insulin (DM), cell lysis (tumor, rhabdo, ischemic bowel, hemolysis, transfusions, resorbing hematomas, hyperthermia, rewarming), hyperkalemic periodic paralysis, ↑ osmolality. Drugs: succinylcholine, aminocaproic acid, digoxin, β-blockers.</p>
<p class="h">Decreased GFR</p>
<p class="noindent1">• Any cause of oliguric or anuric AKI or any cause of end-stage renal disease</p>
<p class="h">Normal GFR but with ↓ renal K excretion</p>
<p class="noindent1">• Normal aldosterone function</p>
<p class="noindent2">↓ EAV (K excretion limited by ↓ <b class="calibre7">distal Na delivery &amp; urine flow</b>): CHF, cirrhosis</p>
<p class="noindent2">Excessive K intake: in conjunction with impairment in K excretion or transcellular shift</p>
<p class="noindent2">Ureterojejunostomy (absorption of urinary K in jejunum)</p>
<p class="noindent1">• <b class="calibre7">Hypoaldosteronism:</b> same as etiologies of hypoaldo RTA (type IV)</p>
<p class="noindent2">↓ renin: DM, NSAIDs, chronic interstitial nephritis, HIV, multiple myeloma, Gordon’s</p>
<p class="noindent2">Normal renin, ↓ aldo synthesis: 1° adrenal disorders, ACEI, ARBs, heparin, ketoconazole</p>
<p class="noindent2">↓ response to aldosterone</p>
<p class="noindent2">Meds: K-sparing diuretics, TMP-SMX, pentamidine, calcineurin inhibitors</p>
<p class="noindent2">Tubulointerstitial disease: sickle cell, SLE, amyloid, diabetes</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Weakness, nausea, paresthesias, palpitations; Renal: ↓ NH<sub class="calibre10">4</sub><sup class="calibre19">+</sup> secretion → acidosis</p>
<p class="noindent1">• ECG: ST depression, peaked T waves, ↓ QT, ↑ PR interval, ↑ QRS width, loss of P wave, sine wave pattern, PEA/VF (ECG: low sens., cardiac arrest can be first manifestation!)</p>
<p class="h">Workup <span class="r1">(</span><span class="r2">Crit Care Med</span> <span class="r1">2008;36:3246)</span></p>
<p class="noindent1">• Rule out pseudohyperkalemia (IVF w/ K, tourniquet, hemolysis, ↑ plt or WBC), rule out transcellular shift</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre23"/>
<col class="calibre23"/>
<col class="calibre23"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="4"><p class="tbodyc"><b class="calibre7">Treatment of Hyperkalemia</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Intervention</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Dose</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Onset</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Comment</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Ca gluconate Ca chloride</b><sup class="calibre27"><a id="fn74-a" class="calibre8"></a><a href="part0010.html#rfn74-a" class="calibre8">a</a></sup></p></td>
<td class="th1"><p class="tbodyc">1–2 amps IV</p></td>
<td class="th1"><p class="tbodyc">&lt;3 min</p></td>
<td class="th1"><p class="tbodyh">Transient effect (30–60 min)</p>
<p class="tbodyh">Stabilizes cell membrane</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">I<b class="calibre7">nsulin</b></p></td>
<td class="th1"><p class="tbodyc">reg insulin 5–10 U IV</p>
<p class="tbodyc">+ 1–2 amps D<sub class="calibre17">50</sub>W</p></td>
<td class="th1"><p class="tbodyc">15–30 min</p></td>
<td class="th1"><p class="tbodyh">Peak 30–60 min, lasts 4–6 h</p>
<p class="tbodyh">↓ K 0.5–1.2 mEq/L</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Bicarbonate</b> (esp. if acidemic)</p></td>
<td class="th1"><p class="tbodyc">1–2 amps IV</p>
<p class="tbodyc">150 mEq in 1 L D<sub class="calibre17">5</sub>W</p></td>
<td class="th1"><p class="tbodyc">15–30 min</p></td>
<td class="th1"><p class="tbodyh">Exchange K for H<sup class="calibre27">+</sup> in cells</p>
<p class="tbodyh">Lasts 5–6 h; ↓ K 0.7 mEq/L</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">β2 agonists</b></p></td>
<td class="th1"><p class="tbodyc">albuterol 10–20 mg inh.</p>
<p class="tbodyc">or 0.5 mg IV</p></td>
<td class="th1"><p class="tbodyc">30–90 min</p></td>
<td class="th1"><p class="tbodyh">Peak 90 min, lasts 2–6 h</p>
<p class="tbodyh">↓ K 0.5–1.4 mEq/L (IV &gt;inh)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">K-binding resins</b></p></td>
<td class="th1"><p class="tbodyc">SPS<sup class="calibre27"><a id="fn74-b" class="calibre8"></a><a href="part0010.html#rfn74-b" class="calibre8">b</a></sup> 15–60 g PO/PR</p>
<p class="tbodyc">patiromer 8.4–25.2 g/d PO</p>
<p class="tbodyc">Na zirconium 5–10 g PO</p></td>
<td class="th1"><p class="tbodyc">4–24 hrs</p>
<p class="tbodyc">hrs-d</p>
<p class="tbodyc">hrs</p></td>
<td class="th1"><p class="tbodyh">Exchange K for cations in gut</p>
<p class="tbodyh">(Na, Ca, H); ↓ K 0.8–1 mEq/L/d.</p>
<p class="tbodyh">Edema &amp; HTN w/ Na zirconium.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Diuretics</b></p></td>
<td class="th1"><p class="tbodyc">furosemide ≥40 mg IV</p></td>
<td class="th1"><p class="tbodyc">30 min</p></td>
<td class="th1"><p class="tbodyh">↓ total body K</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Hemodialysis</b></p></td>
<td class="th1" colspan="2"><p class="tbodyc">Most rapid in 1<sup class="calibre27">st</sup> hr (1 mEq/L)</p></td>
<td class="th1"><p class="tbodyh">↓ total body K <span class="sm">(<i class="calibre6">JASN</i> 2017;28:3441)</span></p></td>
</tr>
</tbody>
</table>
<p class="tfn"><sup class="calibre22"><a id="rfn74-a" class="calibre8"></a><a href="part0010.html#fn74-a" class="calibre8">a</a></sup>CaCl contains more calcium and is typically reserved for codes (↑ risk of tissue necrosis) or via central line</p>
<p class="tfn"><sup class="calibre22"><a id="rfn74-b" class="calibre8"></a><a href="part0010.html#fn74-b" class="calibre8">b</a></sup>~0.4% intestinal necrosis esp. postop, ileus, SBO/LBO, bowel disease (UC), renal txp (<i class="calibre6">Clin Nephro</i> 2016;85:38)</p>
<p class="noindent1">• <b class="calibre7">Assess GFR</b>, if normal, then ✓U<sub class="calibre10">K</sub>, U<sub class="calibre10">Na</sub> (&lt;25 mEq/d ↓ distal Na delivery). ✓ U<sub class="calibre10">K:Cr</sub> (&lt;13 favors ↓ renal K excretion).</p>
<p class="noindent1">• <i class="calibre6">Rate of onset</i> important to note when establishing a treatment plan <span class="r1">(</span><span class="r2">Mayo Clinic</span> <span class="r1">2020;96:744)</span></p>
<p class="noindent1">• <b class="calibre7">Stabilize</b> (initial): 10% CaCl (central) or gluconate (IV). ↑ memb. potential → ↓ excitability</p>
<p class="noindent1">• <b class="calibre7">Redistribute</b>: insulin + dextrose (continuous if NPO), HCO<sub class="calibre10">3</sub>, β<sub class="calibre10">2</sub>-agonists</p>
<p class="noindent1">• <b class="calibre7">Eliminate</b>: SPS, patiromer, Na zirconium, diuretics (w/ saline if preserved renal fxn), consider emergent HD in life-threatening situations</p>
<p class="noindent1">• Patient information for diet education: <a href="http://www.kidney.org/atoz/content/potassium" class="calibre4">http://www.kidney.org/atoz/content/potassium</a></p>
<h2 class="ct"><a id="h58" class="calibre8"></a><a id="page_4-12" class="calibre8"></a><a href="part0003.html#rh65" class="calibre8">KIDNEY DISEASE</a></h2>
<p class="h1cr">A<small class="calibre31">CUTE</small> K<small class="calibre31">IDNEY</small> I<small class="calibre31">NJURY</small> (AKI)</p>
<p class="h">Definition <span class="r1">(</span><span class="r2">KDIGO</span> <span class="r1">2012;2:1)</span></p>
<p class="noindent1">• <b class="calibre7">Stages in ICU correspond to</b> ↑ hospital mortality and LOS <span class="r1">(</span><span class="r2">Crit Care Med</span> <span class="r1">2009;37:2552)</span></p>
<p class="noindent2">Stage 1: Cr ≥0.3 mg/dL in 2d or ↑ Cr ≥50%, or UOP &lt;0.5 mL/kg/h for ≥6h</p>
<p class="noindent2">Stage 2: ↑ Cr 2–3x baseline in 7d or UOP &lt;0.5 mL/kg/h for ≥12h</p>
<p class="noindent2">Stage 3: ↑ 3x baseline in 7d, UOP &lt;0.3 mL/kg/h for ≥24h, anuria ≥12h, or Cr &gt;4</p>
<p class="noindent1">• <i class="calibre6">Cannot</i> estimate GFR using Cr in setting of AKI or ∆’ing Cr (requires steady state)</p>
<p class="h">Workup <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2014;371:55)</span></p>
<p class="noindent1">• <b class="calibre7">H&amp;P:</b> meds, contrast, or other nephrotoxins; ↓ PO intake, HoTN, infxn/sepsis; trauma, myalgias; BPH/retention. Search for insult 24–48 hr prior ↑ Cr. VS, vol status, rash.</p>
<p class="noindent1">• <b class="calibre7">Urine evaluation:</b> output, urinalysis, <b class="calibre7">sediment</b>, electrolytes, and osmolality</p>
<p class="noindent1">• <b class="calibre7">Fractional excretion Na (FE<sub class="calibre10">Na</sub>)</b> = (U<sub class="calibre10">Na</sub>/P<sub class="calibre10">Na</sub>)/(U<sub class="calibre10">Cr</sub>/P<sub class="calibre10">Cr</sub>); if diuretic, ✓ FE<sub class="calibre10">UN</sub>=(U<sub class="calibre10">UN</sub>/P<sub class="calibre10">UN</sub>)/(U<sub class="calibre10">Cr</sub>/P<sub class="calibre10">Cr</sub>)</p>
<p class="noindent1">• Renal U/S or CT: r/o obstruction &amp; cortical atrophy in chronic kidney disease</p>
<p class="noindent1">• Serologies (if indicated): see “Glomerular Disease”</p>
<p class="noindent1">• Renal biopsy (microscopy, IF, and EM): if etiology unclear (esp. if proteinuria/hematuria). Relative contraindic.: SBP&gt;150, ASA/NSAID, anticoag, cirrhosis. DDAVP if GFR &lt;45.</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Etiologies and Diagnosis of Acute Kidney Injury</b> <span class="sm">(<i class="calibre6">Ann Inter Med</i> 2017;9:66)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1" colspan="2"><p class="tbody"><b class="calibre7">Etiologies</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">UA, Sediment, Indices</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Prerenal</b></p></td>
<td class="th1"><p class="tbodyh">↓ <b class="calibre7">Effective arterial volume</b> <span class="sm">(<i class="calibre6">NEJM</i> 2007;357:797)</span> Hypovolemia, ↓ CO (CHF), ↓ oncotic pressure (cirrhosis, nephrotic), vasodilation (sepsis)</p>
<p class="tbodyh">Δ <b class="calibre7">local renal perfusion:</b> NSAIDs, ACEI/ARB, contrast, calcineurin inhib, HRS, hyperCa</p>
<p class="tbodyh"><b class="calibre7">Large vessel:</b> RAS (bilateral + ACEI), VTE, dissection, abd compart. synd. (renal vs. compress), vasculitis</p></td>
<td class="th1"><p class="tbodyh">Bland</p>
<p class="tbodyh">Transparent hyaline casts</p>
<p class="tbodyh">FE<sub class="calibre17">Na</sub> &lt;1%, BUN/Cr &gt;20</p>
<p class="tbodyh">FE<sub class="calibre17">UN</sub> ≤35%</p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="4"><p class="tbodyc"><b class="calibre7">Intrinsic</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Acute tubular necrosis (ATN)</b></p>
<p class="tbodyh"><i class="calibre6">Severe ischemia, sepsis, CIN</i> (↓ RBF + toxin)</p>
<p class="tbodyh"><i class="calibre6">Toxins</i></p>
<p class="tbodyh">Drugs: vanc, AG, cisplatin, foscarnet, HES (starch), IVIG, pentamidine, amphotericin, tenofovir</p>
<p class="tbodyh">Pigments: Hb, myoglobin <span class="sm">(<i class="calibre6">NEJM</i> 2009;361:62)</span></p>
<p class="tbodyh">Monoclonal: Ig light chains <span class="sm">(<i class="calibre6">Blood</i> 2010;116:1397)</span></p>
<p class="tbodyh">Crystals: UA, ACV, MTX, indinavir, oral NaPO<sub class="calibre17">4</sub></p></td>
<td class="th1"><p class="tbodyh">Pigmented granular muddy brown casts</p>
<p class="tbodyh">± RBCs &amp; protein from tubular damage</p>
<p class="tbodyh">FE<sub class="calibre17">Na</sub> &gt;2%, BUN/Cr &lt;20 (except pigment, CIN)</p>
<p class="tbodyh">FE<sub class="calibre17">UN</sub> &gt;50%</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Acute interstitial nephritis (AIN)</b></p>
<p class="tbodyh"><i class="calibre6">Allergic:</i> β-lactams, sulfa drugs, NSAIDs, PPIs</p>
<p class="tbodyh"><i class="calibre6">Infection:</i> pyelo, viral, legionella, TB, leptospirosis</p>
<p class="tbodyh"><i class="calibre6">Infiltrative:</i> sarcoid, lymphoma, leukemia</p>
<p class="tbodyh"><i class="calibre6">Autoimmune:</i> Sjögren’s, TINU, IgG4, SLE, ICIs</p></td>
<td class="th1"><p class="tbodyh">WBCs, WBC casts, ± RBCs w/ neg UCx</p>
<p class="tbodyh">⊕ urine eos in abx</p>
<p class="tbodyh">⊕ lymphs in NSAIDs</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Small-med vessel:</b> chol emboli, PAN, TMAs (TTP, HUS, atypical HUS, DIC, preeclampsia, APS, malignant HTN, scleroderma renal crisis)</p></td>
<td class="th1"><p class="tbodyh">± RBCs</p>
<p class="tbodyh">⊕ urine eos in chol emboli</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Glomerulonephritis</b> (see “Glomerular Disease”)</p></td>
<td class="th1"><p class="tbodyh">Dysmorphic RBCs, RBC casts</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Post</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Bladder neck:</b> BPH, prostate cancer, neurogenic bladder, anticholinergic meds</p>
<p class="tbodyh"><b class="calibre7">Ureteral</b> (bilateral or unilateral in single kidney): malig, LAN, retroperitoneal fibrosis, nephrolithiasis</p></td>
<td class="th1"><p class="tbodyh">Bland ± non-dysmorphic RBCs, WBC, crystals</p></td>
</tr>
</tbody>
</table>
<p class="h">General treatment <span class="r1">(</span><span class="r2">CJASN</span> <span class="r1">2008;3:962)</span></p>
<p class="noindent1">• Prerenal: isotonic IVF ≈ alb <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2004;350:22)</span>. No clear benefit of balanced crystalloids (eg, LR) over normal saline <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;378:829 &amp; 2022;386:815)</span>.</p>
<p class="noindent1">• Avoid nephrotoxic insults (meds and contrast); renally dose medications</p>
<p class="noindent1">• Optimize hemodynamics (both MAP &amp; CO) and maintain euvolemia <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2007;357:797)</span></p>
<p class="noindent1">• <i class="calibre6">No</i> benefit to dopamine <span class="r1">(</span><span class="r2">Annals</span> <span class="r1">2005;142:510)</span>, diuretics <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2002;288:2547)</span>, or mannitol</p>
<p class="h">Managing complications</p>
<p class="noindent1">• May take 1–3 wk to recover from ATN; anticipate volume overload, ↑ K, ↑ PO<sub class="calibre10">4</sub>, acidosis</p>
<p class="noindent1">• Episodes of AKI ↑ risk of CKD progression, even after recovery <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2014;371:58)</span></p>
<p class="noindent1">• Indications for urgent dialysis (when condition refractory to conventional therapy)</p>
<p class="noindent2"><b class="calibre7">A</b>cid-base disturbance: refractory acidemia</p>
<p class="noindent2"><b class="calibre7">E</b>lectrolyte disorder: hyperK; hyperCa, hyperPO<sub class="calibre10">4</sub>, tumor lysis syndrome</p>
<p class="noindent2"><a id="page_4-13" class="calibre4"></a><b class="calibre7">I</b>ntoxications (<a href="http://www.extrip-workgroup.org/" class="calibre4">http://www.extrip-workgroup.org/</a>): Poison Control (1-800-222-1222)</p>
<p class="noindent3">Indicated for: methanol, ethylene glycol, metformin, Li, valproic acid, salicylates, barbiturates, theophylline, thallium</p>
<p class="noindent3">Consider for: carbamazepine, APAP, dig (Rx Digibind), dabigatran (Rx idarucizumab)</p>
<p class="noindent2"><b class="calibre7">O</b>verload: refractory hypervolemia → hypoxemia (eg, CHF)</p>
<p class="noindent2"><b class="calibre7">U</b>remia: pericarditis, encephalopathy, bleeding</p>
<p class="noindent1">• In stage 3 AKI, wait until above indication or oliguria &gt;72 hrs <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2016;375:122;</span> <span class="r2">Lancet</span> <span class="r1">2020;395:1506)</span>. If oliguria &gt;72 hrs, further delaying until urgent indication ↑ mortality <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2021;397:1293)</span>.</p>
<p class="h1cr">D<small class="calibre31">ISEASE</small>-S<small class="calibre31">PECIFIC</small> M<small class="calibre31">ANAGEMENT</small></p>
<p class="h">Acute interstitial nephritis <span class="r">(AIN)</span> <span class="r1">(</span><span class="r2">CJASN</span> <span class="r1">2017;12:2046 &amp;</span> <span class="r2">JASN</span> <span class="r1">2020;31:435)</span></p>
<p class="noindent1">• Commonly drug-induced: β-lactams, sulfa drugs, NSAIDs, PPIs, quinolones, allopurinol</p>
<p class="noindent1">• If suspected, prompt removal of offending drug; ? early steroids w/in 7d of dx</p>
<p class="noindent1">• Rechallenging after suspected ICI-induced AIN may depend on oncology natural history</p>
<p class="h">Cardiorenal syndrome <span class="r">(CRS)</span> <span class="r1">(</span><span class="r2">CJASN</span> <span class="r1">2017;12:1624)</span></p>
<p class="noindent1">• Multifactorial pathophys including: 1) ↓ CO, 2) ↑ renal venous congestion, 3) ↑ RAAS</p>
<p class="noindent1">• Bidirectionality: acute CHF → AKI, and oliguric AKI can worsen CHF <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2008;52:1527)</span></p>
<p class="noindent1">• Rx: <b class="calibre7">IV loop diuretics</b> (bypass gut edema; dosing below); no diff. between high vs. low dose and bolus vs. gtt <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2011;364:797)</span>. No clinical benefit: dopa, nesiritide, ultrafilt.</p>
<p class="noindent1">• Prognosis: 7% ↑ mortality a/w each 10 mL/min ↓ eGFR in ADHF <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2006;47:1987)</span></p>
<p class="h">Contrast-induced acute kidney injury <span class="r">(CIAKI)</span> <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2019;380:2146)</span></p>
<p class="noindent1">• Risk factors: CKD, DM, CHF, age, hypotension, ↑ contrast volume <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2004;44:1393)</span></p>
<p class="noindent1">• AKI 24–48 h post contrast, peaks 3–5 d, resolves 7–10 d (consider chol emboli if does not)</p>
<p class="noindent1">• Prevention: consider if eGFR &lt;60 (espec. w/ proteinuria), DM, MI, HoTN <span class="r1">(</span><span class="r2">CJASN</span> <span class="r1">2013;8:1618)</span></p>
<p class="noindent3"><b class="calibre7">Isotonic IV fluids:</b> may be helpful if high risk <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2017;389:1312)</span></p>
<p class="noindent3">Outpatients: 3 mL/kg/h × 1 h prior, 1–1.5 mL/kg/h × 6 h after <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2004;291:2328)</span></p>
<p class="noindent3">Inpatients: 1 mL/kg/h × 6–12 h pre, intra, post-procedure <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2014;383:1814)</span></p>
<p class="noindent2">Hold ACEI/ARB <span class="r1">(</span><span class="r2">AJKD</span> <span class="r1">2012;60:576)</span>, NSAIDs, diuretics. Min. contrast &amp; use iso-osmolar.</p>
<p class="noindent1">• Nephrogenic systemic fibrosis: fibrosis of skin, joints, internal organs ~2–4 wk post gado exposure in CKD 4–5 <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2009;53:1621)</span>. Postgado HD encouraged, though limited data.</p>
<p class="h">Hepatorenal syndrome <span class="r">(HRS;</span> <i class="calibre6">see “Cirrhosis”;</i> <span class="r2">AJKD</span><span class="r1"> 2013;62:1198</span><span class="r">)</span></p>
<p class="noindent1">• <b class="calibre7">Albumin</b> + <i class="calibre6">either</i> IV vasopressors (norepi, terlipressin) <i class="calibre6">or</i> octreotide &amp; midodrine</p>
<p class="h">Obstructive diseases</p>
<p class="noindent1">• Dx: renal U/S if undifferentiated or CT abd/pelvic (I<sup class="calibre19">–</sup>) if suspect nephrolithiasis</p>
<p class="noindent1">• Rx: Foley if urethra vs. perc. nephrostomy if above ureters (eg, stones), tamsulosin/finasteride</p>
<p class="noindent1">• Watch for post-obstructive diuresis after relieving blockage, replace ½ UOP w/ ½ NS.</p>
<p class="noindent2">Hemorrhagic cystitis (rapid ∆ in size of bladder vessels); avoid by decompressing slowly.</p>
<p class="h">Polycystic kidney disease <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2008;359:1477; 2017;377:1988)</span></p>
<p class="noindent1">• Mostly AD <i class="calibre6">PKD1/PKD2</i> mutations → renal cysts. PKD1 (85%) younger-onset ESRD.</p>
<p class="noindent1">• Rx: hydration, low-salt diet; tolvaptan reduces GFR decline. Family genetic screening.</p>
<p class="h">Rhabdomyolysis <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2009;361:62)</span></p>
<p class="noindent1">• Pathophys: myoglobin-induced oxidant injury, vasoconstriction, myoglobin precipitation &amp; pre-renal (extravasation). Can lead to ↓ Ca, ↑ K, and ↑ PO<sub class="calibre10">4</sub>.</p>
<p class="noindent1">• Diagnosis: UA ⊕ for heme but 0 RBCs (ie, myoglobinuria)</p>
<p class="noindent1">• Risk of AKI when CK &gt;20,000. Rhabdo and mortality risk score: <span class="r2">JAMA Int Med</span> <span class="r1">2013;173:1821</span>.</p>
<p class="noindent1">• Aggressive IVF (tailor IVF to target UOP ~3 mL/kg). If urine pH &lt;6.5, consider NaHCO<sub class="calibre10">3</sub> ✓ K &amp; Ca frequently, trend CK. Monitor for compartment syndrome.</p>
<p class="h">Scleroderma renal crisis <span class="r1">(</span><span class="r2">Nature Neph</span> <span class="r1">2016;12:678)</span></p>
<p class="noindent1">• 5–20% diffuse cutaneous SSc w/ narrowing glomerular vessels. Sx: renal failure, severe HTN, encephalopathy. Rx: max ACEi for BP control.</p>
<p class="h">COVID-19 associated AKI <span class="r1">(</span><span class="r2">Am J Physiol Renal Physiol</span> <span class="r1">2021;4:403)</span></p>
<p class="noindent1">• 17% of inPts. ATN &gt;collapsing FSGS (high-risk <i class="calibre6">APOL1</i> genotype). ↑ clotting risk w/ RRT</p>
<p class="h">Thrombotic microangiopathies <span class="r">(TMAs):</span> <i class="calibre6">see “Hematology”</i></p>
<p class="h1cr">C<small class="calibre31">HRONIC</small> K<small class="calibre31">IDNEY</small> D<small class="calibre31">ISEASE</small> (CKD)</p>
<p class="h">Definition and etiologies <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2021;10302:786)</span></p>
<p class="noindent1">• <b class="calibre7">GFR</b> &lt;60 for ≥3 mo <i class="calibre6">and</i>/<i class="calibre6">or</i> <b class="calibre7">kidney damage</b> (albuminuria, structural abnormality)</p>
<p class="noindent1">• Prevalence 15% in U.S.</p>
<p class="noindent1">• Albuminuria predicts all-cause &amp; CV mortality, CKD progression <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2004;351:1296)</span></p>
<p class="noindent1">• Cr poor estimate of GFR, use equation (<a href="https://www.kidney.org/professionals/kdoqi/gfr_calculator" class="calibre4">https://www.kidney.org/professionals/kdoqi/gfr_calculator</a>)</p>
<p class="noindent2">Cystatin-C–based formula less influenced by race than Cr-based <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2021;385:1737)</span></p>
<p class="noindent1"><a id="page_4-14" class="calibre4"></a>• Etiologies: DM (45%), HTN/RAS (27%), glomerular (10%), interstitial (5%), PKD (2%), congenital, drugs, myeloma, repeated insults (eg, Mesoamerican nephropathy)</p>
<p class="noindent1">• Progression to ESRD: kidney failure risk equation <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2016;315:164; <a href="http://kidneyfailurerisk.com" class="calibre4">kidneyfailurerisk.com</a>)</span></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Stages of CKD</b> <span class="sm">(<i class="calibre6">Kid Int</i> 2013;3[Suppl]:5)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">GFR Stage</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">GFR</b> mL/min/1.73 m<sup class="calibre27">2</sup></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Goals</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">1 (nl or ↑ GFR)</p></td>
<td class="th1"><p class="tbodyc">&gt;90</p></td>
<td class="th1"><p class="tbody">Dx/Rx of underlying condition &amp; comorbidities, slow progression; cardiovascular risk reduction</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">2 (mild)</p></td>
<td class="th1"><p class="tbodyc">60–89</p></td>
<td class="th1"><p class="tbody">Estimate progression</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">3a (mild-mod)</p></td>
<td class="th1"><p class="tbodyc">45–59</p></td>
<td class="th1"><p class="tbody">Evaluate and treat complications</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">3b (mod-severe)</p></td>
<td class="th1"><p class="tbodyc">30–44</p></td>
<td class="th1"><p class="tbody">Evaluate and treat complications</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">4 (severe)</p></td>
<td class="th1"><p class="tbodyc">15–29</p></td>
<td class="th1"><p class="tbody">Prepare for renal replacement therapy (RRT)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">5 (kidney failure)</p></td>
<td class="th1"><p class="tbodyc">&lt;15 or dialysis</p></td>
<td class="th1"><p class="tbody">Dialysis if uremic/volume overload; Tx</p></td>
</tr>
<tr class="calibre15">
<td class="th1" colspan="3"><p class="tbody"><b class="calibre7">Albuminuria stage</b> based on albuminuria (mg/d) or spot urine alb (mg) to Cr (g) ratio</p>
<p class="tbody">Stages: A1 = &lt;30 (normal/mild); A2 = 30–300 (moderate); A3 = &gt;300 (severe)</p></td>
</tr>
</tbody>
</table>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Signs and Symptoms of Uremia</b> <span class="sm">(<i class="calibre6">NEJM</i> 2018;379:669)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody">General</p></td>
<td class="th1"><p class="tbody">Nausea, anorexia, malaise, uremic fetor, metallic taste, hypothermia</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Skin</p></td>
<td class="th1"><p class="tbody">Uremic frost (white crystals in &amp; on skin), pruritus, calciphylaxis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Neurologic</p></td>
<td class="th1"><p class="tbody">Encephalopathy (Δ MS, ↓ memory &amp; attention), seizures, neuropathy, impaired sleep, restless leg syndrome</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Cardiovascular</p></td>
<td class="th1"><p class="tbody">Pericarditis, atherosclerosis, HTN, CHF, cardiomyopathy (LVH)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Hematologic</p></td>
<td class="th1"><p class="tbody">Anemia, bleeding (due to platelet dysfunction and Epo deficiency)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Metabolic</p></td>
<td class="th1"><p class="tbody">↑ K, ↑ PO<sub class="calibre17">4</sub>, acidosis, ↓ Ca, 2° hyperparathyroidism, osteodystrophy</p></td>
</tr>
</tbody>
</table>
<p class="h">Complications &amp; treatment <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2019;322:1294;</span> <span class="r2">KI</span><span class="r1"> 2021;99:S1)</span></p>
<p class="noindent1">• <b class="calibre7">General:</b> renal referral when GFR &lt;30 or proteinuria, access planning (avoid subclavian lines, preserve an arm by avoiding phlebotomy, BP measurements, IVs)</p>
<p class="noindent1">• <b class="calibre7">CV risk reduction:</b> consider usual preventive Rx including statin, βB, etc.</p>
<p class="noindent1">• <b class="calibre7">Dietary restrictions:</b> Na (if HTN), K (if oliguric or hyperkalemic), PO<sub class="calibre10">4</sub>, mod protein.</p>
<p class="noindent1">• <b class="calibre7">Diabetes:</b> strict glc control; ACEI/ARB, SGLT2i and MRA <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2020;383:2219)</span> slow CKD progression (↓ glomerular pressure)</p>
<p class="noindent1">• <b class="calibre7">SGLT2i:</b> in proteinuric CKD (min eGFR 25-30) w/ or w/o DM, transient ↓ in eGFR (&lt;5) but then 30-40% ↓ risk of CKD progression &amp; ↓ mortality <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2019;380:2295 &amp; 2020;383:1436)</span></p>
<p class="noindent1">• <b class="calibre7">BP control:</b> goal ideally &lt;120/80, a/w ↓ mortality. ACEI or ARB, not both. For outPts, ✓ Cr &amp; K in 1–2 wk, d/c if Cr ↑ 30% or K &gt;5.4 (after dietary Δ &amp; loop diuretic).</p>
<p class="noindent1">• <b class="calibre7">Metabolic acidosis:</b> sodium bicarbonate or sodium citrate if low HCO<sub class="calibre10">3</sub> <span class="r1">(</span><span class="r2">JASN</span> <span class="r1">2015;26:515)</span></p>
<p class="noindent1">• <b class="calibre7">Hyperkalemia:</b> 2-g K diet, see “Potassium Homeostasis”</p>
<p class="noindent1">• <b class="calibre7">Anemia:</b> goal Hb 10–11.5 g/dL, worse outcomes if target higher <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2009;361:2019)</span></p>
<p class="noindent2">epoetin (start 80–120 U/kg SC, divided 3×/wk) or darbepoetin (0.75 mg/kg q 2 wk)</p>
<p class="noindent2">iron supplementation to keep transferrin sat &gt;20% (often given IV in HD Pts).</p>
<p class="noindent2">HIF inhib. ↑ endogenous EPO production, not yet approved <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2021;385:2313 &amp; 2325)</span>.</p>
<p class="noindent1">• <b class="calibre7">Uremic bleeding:</b> desmopressin (dDAVP) 0.3 μg/kg IV or 3 μg/kg intranasally</p>
<p class="noindent1">• <b class="calibre7">2</b>° <b class="calibre7">hyperPTH:</b> ↑ PO<sub class="calibre10">4</sub>, ↑ FGF-23, ↓ calcitriol, &amp; ↓ Ca → ↑ PTH → renal osteodystrophy</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre23"/>
<col class="calibre23"/>
<col class="calibre23"/>
</colgroup>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th2"><p class="tbody"><b class="calibre7">CKD stage</b></p></td>
<td class="th2"><p class="tbodyc">3</p></td>
<td class="th2"><p class="tbodyc">4</p></td>
<td class="th2"><p class="tbodyc">5</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Target PTH (pg/mL)</b></p></td>
<td class="th1"><p class="tbodyc">35–70</p></td>
<td class="th1"><p class="tbodyc">70–110</p></td>
<td class="th1"><p class="tbodyc">150–600</p></td>
</tr>
</tbody>
</table>
<p class="noindent2">Phosphorus binders (<i class="calibre6">take with meals!</i>) <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2010;362:1312)</span>. Non-Ca–based binders (eg, sevelamer) a/w ↓ mort. compared to Ca-based <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2013;382:1268)</span>.</p>
<p class="noindent2">If PTH above goal then start vit. D (if 25-(OH)D &lt;30) or 1,25-(OH)D analogue (calcitriol); stop if ↑ Ca <span class="r1">(</span><span class="r2">AJKD</span> <span class="r1">2009;53:408)</span></p>
<p class="noindent2">Cinacalcet (parathyroid Ca-sensing receptor agonist) if ↑ PTH despite phosphorus binders ± vit. D analogue <span class="r1">(</span><span class="r2">CJASN</span> <span class="r1">2016;11:161)</span>; consider parathyroidectomy</p>
<p class="noindent1">• <b class="calibre7">Calciphylaxis</b> (calcific uremic arteriopathy, <span class="r2">NEJM</span><span class="r1"> 2018;378:1704</span>)</p>
<p class="noindent2">Pathophys: calcification of media in dermal small- to med-sized blood vessels &amp; SC fat → ischemia and skin necrosis w/ painful lesions <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2007;356:1049)</span></p>
<p class="noindent2">Risk factors: ESRD, ♀&gt;♂, DM, vit K def, obesity, warfarin, local trauma, thrombophilias</p>
<p class="noindent2">Dx: skin bx, but limitations <span class="r1">(</span><span class="r2">Kidney Int</span> <span class="r1">2018;94:390)</span>; bone scan used in support of dx</p>
<p class="noindent2">Rx: ↓ risk factors, wound care/surgical debridement, manage hyperPTH, d/c vit D, Ca, &amp; warfarin (DOAC okay). Pain control, palliative care, ? Na thiosulfate.</p>
<p class="noindent2">Prognosis: 60% 1-y mortality in ESRD Pts <span class="r1">(</span><span class="r2">AJKD</span> <span class="r1">2015;66:133)</span></p>
<p class="noindent1">• <b class="calibre7">Anticoag:</b> ESRD at ↑ bleed risk; if using DOAC, consider apixiban &gt;rivaroxaban &gt;dabigatran due to protein binding/renal clearance <span class="r1">(</span><span class="r2">JASN</span> <span class="r1">2017;28:2241)</span></p>
<p class="noindent1">• <b class="calibre7">Transplant evaluation</b></p>
<p class="h1cr"><a id="page_4-15" class="calibre8"></a>D<small class="calibre31">IURESIS</small></p>
<p class="h">General considerations</p>
<p class="noindent1">• ↑ Na &amp; H<sub class="calibre10">2</sub>O excretion for treatment of HTN or edema in CHF, renal failure, and cirrhosis</p>
<p class="noindent1">• Daily wt most effective method of documenting successful diuresis</p>
<p class="h">Loop diuretics <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2017;377:1964)</span></p>
<p class="noindent1">• <b class="calibre7">Drugs:</b> furosemide (Lasix), torsemide, bumetanide (Bumex), ethacrynic acid</p>
<p class="noindent1">• <b class="calibre7">Mech:</b> inhib NaK2Cl cotransporter in thick ascending limb (ThAL, site of 25% Na reabsorp) → ↓ medullary osmotic gradient &amp; ↓ free H<sub class="calibre10">2</sub>O reabsorption via ADH</p>
<p class="noindent2">Transient venodilation may aid in pulmonary congestion <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">1973;288:1087)</span></p>
<p class="noindent2">Response is fxn of amt of drug excreted; ∴ ↑ dose needed in renal insufficiency, CHF</p>
<p class="noindent2">Sigmoidal dose response curve; ∴ ↑ dose until induce diuresis, ↑↑ dose beyond that point yields diminishing returns compared with ↑ frequency of dosing</p>
<p class="noindent1">• <b class="calibre7">Dosing:</b> bioavailability PO furosemide ~50%, PO torsemide &amp; bumetanide ~90%</p>
<p class="noindent2">40 mg IV = 80 mg PO Lasix = 20 mg PO/IV torsemide = 1 mg IV/PO bumetanide</p>
<p class="noindent2">Dose furosemide bid-qid; qd dosing can yield initial diuresis, but then anti-natriuresis. Cont. vs. bolus IV similar in acute CHF <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2011;364:797)</span>. Ethacrynic acid if sulfa allergy.</p>
<p class="noindent2">? ↑ diuresis w/ co-administration of albumin if ↓ serum albumin <span class="r1">(</span><span class="r2">Crit Care Med</span> <span class="r1">2005;33:1681)</span></p>
<p class="noindent1">• <b class="calibre7">Adverse effects:</b> ↑ Na, ↓ K, ↓ Mg, ↓ Ca, hyperuricemia, ototoxicity, hypersensitivity (sulfa)</p>
<p class="h">Thiazide diuretics <span class="r1">(</span><span class="r2">JASN</span> <span class="r1">2017;28:3414)</span></p>
<p class="noindent1">• <b class="calibre7">Drugs:</b> hydrochlorothiazide (HCTZ), chlorothiazide (Diuril), metolazone (Zaroxolyn)</p>
<p class="noindent1">• <b class="calibre7">Mech:</b> inhib Na-Cl cotransporter in the distal convoluted tubule (DCT); 5% Na reabsorp</p>
<p class="noindent2"><b class="calibre7">synergistic with loop diuretic</b>, esp. if chronic loop use</p>
<p class="noindent2">↓ effect when GFR &lt;30, <i class="calibre6">except metolazone,</i> which is still effective in renal insufficiency</p>
<p class="noindent1">• <b class="calibre7">Dosing:</b> give 30 min prior to loop diuretic</p>
<p class="noindent1">• <b class="calibre7">Adverse effects:</b> ↓ Na, ↓ K, ↓ Mg, ↑ Ca, HLD, pancreatitis, ↑ glc, hypersensitivity</p>
<p class="h">K-sparing diuretics <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2017;377:1964)</span></p>
<p class="noindent1">• <b class="calibre7">Drugs:</b> spironolactone (Aldactone), amiloride, triamterene, eplerenone</p>
<p class="noindent1">• <b class="calibre7">Mech:</b> ↓ Na reabsorption (~1%) in collecting duct (amiloride/triamterene inhibit principal cell Na channel [ENaC]; spironolactone/eplerenone inhibit mineralocorticoid receptor).</p>
<p class="noindent2">Relatively weak natriuretic activity, useful in combination with thiazide or in cirrhosis.</p>
<p class="noindent1">• <b class="calibre7">Adverse effects:</b> ↑ K (esp. w/ ACEI), metabolic acidosis, gynecomastia (spironolactone)</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre25"/>
<col class="calibre39"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Approach to Diuresis</b> <span class="sm">(if inadequate diuresis, go to next step)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Step</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Action</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">1</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Loop diuretic PO:</b> ✓ response at 1–3 h, redose at 2× prior dose if needed</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">2</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Add thiazide diuretic PO</b> (potentiates response to loop diuretic)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">3</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Loop diuretic IV:</b> bolus bid–qid ± thiazide (<i class="calibre6">may start here if inPt</i>) ↑ dose w/ ↑ Cr; initial effective IV Lasix dose ≈ 30 × Cr (ie, if Cr = 4 → 120 mg IV)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">4</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Loop diuretic infusion:</b> bolus + continuous IV infusion ± thiazide (PO or IV)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">5</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">RRT:</b> consider ultrafiltration, CRRT, or HD</p></td>
</tr>
</tbody>
</table>
<p class="h">Disease state specific regimens</p>
<p class="noindent1">• Renal insufficiency: loop diuretic (↑ dose to achieve effective delivery to ThAL) ± thiazide</p>
<p class="noindent1">• CHF: loop diuretic (↑ frequency over ↑ dose), IV for gut edema + thiazide (watch K &amp; Mg)</p>
<p class="noindent1">• Nephrotic syndrome: urinary albumin binds secreted loop diuretic, use 2–3× normal dose</p>
<p class="noindent1">• Cirrhosis: spironolactone (blocks 2° hyperaldosteronism) + Lasix in 2.5:1 ratio</p>
<p class="noindent1">• Severe metabolic alkalosis: acetazolamide &amp; treat underlying cause</p>
<p class="h1cr">R<small class="calibre31">ENAL</small> R<small class="calibre31">EPLACEMENT</small> <small class="calibre31">AND</small> D<small class="calibre31">IALYSIS</small></p>
<p class="h">General</p>
<p class="noindent1">• Acute indications: see “AKI”; choices CVVH vs. HD</p>
<p class="noindent1">• Chronic indications: timing of RRT initiation should factor in Pt QoL, uremic sx, risk of development of urgent/acute indications; modalities PD vs. HD (no clear diff in outcomes)</p>
<p class="noindent1">• Outcomes of ESRD: death from CVD (50%), infxn (30%), withdrawal of care (20%)</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre40"/>
<col class="calibre41"/>
<col class="calibre41"/>
<col class="calibre41"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="4"><p class="tbodyc"><b class="calibre7">Modalities</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"> </p></td>
<td class="th1"><p class="tbody"><b class="calibre7">HD</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">CVVH</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">PD</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Physiology</b></p></td>
<td class="th1"><p class="tbody">Diffusion</p></td>
<td class="th1"><p class="tbody">Convection</p></td>
<td class="th1"><p class="tbody">Diffusion</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Access</b></p></td>
<td class="th1"><p class="tbody">AV fistula/graft or CVC</p></td>
<td class="th1"><p class="tbody">CVC</p></td>
<td class="th1"><p class="tbody">Peritoneal catheter</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Prescription</b></p></td>
<td class="th1"><p class="tbody">Duration, volume goal; K, Na, Ca, HCO<sub class="calibre17">3</sub> in bath, anticoag</p></td>
<td class="th1"><p class="tbody">Volume goal, K &amp; Ca in replacement fluid (HCO<sub class="calibre17">3</sub> vs. citrate)</p></td>
<td class="th1"><p class="tbody">PD fluid (dextrose, icodextrin), dwell time, # cycles</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Complic.</b></p></td>
<td class="th1"><p class="tbody">HoTN, arrhythmia, disequilibrium syndrome<sup class="calibre27"><a id="fn80-s1" class="calibre8"></a><a href="part0010.html#rfn80-s1" class="calibre8">*</a></sup> if very high BUN, ↑ CO HF</p></td>
<td class="th1"><p class="tbody">HoTN, ↓ PO<sub class="calibre17">4</sub>, ↓ iCa (citrate toxicity in hepatic dysfxn)</p></td>
<td class="th1"><p class="tbody">Peritonitis, ↑ glc, ↓ albumin, R pleural effusion</p></td>
</tr>
</tbody>
</table>
<p class="tfn"><sup class="calibre22"><a id="rfn80-s1" class="calibre8"></a><a href="part0010.html#fn80-s1" class="calibre8">*</a></sup>Disequilibrium syndrome: sx cerebral edema due to H<sub class="calibre24">2</sub>O shifts after urea removal</p>
<p class="h"><a id="page_4-16" class="calibre4"></a>Hemodialysis (HD) <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2010;363:1833)</span></p>
<p class="noindent1">• Solute removal across <i class="calibre6">semipermeable</i> membrane, countercurrent blood &amp; dialysate flow</p>
<p class="noindent2">Volume removal: Na/H<sub class="calibre10">2</sub>O ultrafiltered via transmembrane pressure (TMP) gradient</p>
<p class="noindent2">Solutes: Cr, urea, K diffuse from blood → dialysate, HCO<sub class="calibre10">3</sub> from dialysate → blood</p>
<p class="noindent2">Solute removal inversely proportional to size ∴ effective removal of K, urea, Cr, not PO<sub class="calibre10">4</sub></p>
<p class="noindent1">• 6× vs. 3×/wk improved HTN, LV mass, QoL, but ↑ vasc issues <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2010;363:2287)</span>; w/ 3×/wk HD, ↑ mortality risk during 2-d interval (Sa–Tu or Fri–Mo) <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2011;365:1099)</span></p>
<p class="noindent1">• Fever w/ catheter: empiric abx (vanc + GNR coverage qHD). GPC &gt;GNR &gt;mixed/fungal. Remove/replace catheter (depends on organism), “lock” abx <span class="r1">(</span><span class="r2">JASN</span> <span class="r1">2014;25:2927)</span>.</p>
<p class="noindent1">• Central vein stenosis: assoc. with longer HD duration, tunneled catheters. HeRO grafts bypass subclavian stenosis with flow into central vein <span class="r1">(</span><span class="r2">J Vasc Access</span> <span class="r1">2016;17:138)</span>.</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre33"/>
<col class="calibre18"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Vascular Access</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"> </p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Advantages</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Disadvantages</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">AV fistula</b></p></td>
<td class="th1"><p class="tbody">Highest patency</p>
<p class="tbody">Lowest risk of bacteremia</p>
<p class="tbody">Lowest mortality <span class="sm">(<i class="calibre6">JASN</i> 2013;24:465)</span></p></td>
<td class="th1"><p class="tbody">Long maturation time (2–6 mo)</p>
<p class="tbody">Primary nonfunction (20%)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">AV graft</b></p></td>
<td class="th1"><p class="tbody">Easier to create than AVF</p>
<p class="tbody">Maturation time (2–3 wk)</p></td>
<td class="th1"><p class="tbody">Poor 1° patency, often requiring thrombectomy or angioplasty</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Catheter</b></p></td>
<td class="th1"><p class="tbody">Immediate use</p>
<p class="tbody">Use as bridge to AVF/AVG</p></td>
<td class="th1"><p class="tbody">Highest risk of bacteremia</p>
<p class="tbody">↓ blood flow → ↓ HD efficiency</p></td>
</tr>
</tbody>
</table>
<p class="h">Continuous veno-venous hemofiltration (CVVH) <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2012;367:26)</span></p>
<p class="noindent1">• <i class="calibre6">Hemofiltration</i> rather than dialysis. Blood under pressure passes down one side <i class="calibre6">highly permeable</i> membrane filtering H<sub class="calibre10">2</sub>O and solutes via TMP gradient (convective clearance); filtrate discarded. Replacement fluid infused (solute concentration similar to plasma, except no urea, Cr, PO<sub class="calibre10">4</sub>). Fluid balance by adjusting filtrate/replacement fluid.</p>
<p class="noindent1">• Replacement fluid rate determines clearance. Choice of replacement fluid buffer:</p>
<p class="noindent2"><b class="calibre7">HCO</b><sub class="calibre10">3</sub> (+ heparin to prevent clotting, although can be run heparin-free)</p>
<p class="noindent2"><b class="calibre7">citrate:</b> hepatically metabolized to HCO<sub class="calibre10">3</sub>, ∴ cannot be given in cirrhosis/liver failure. Provides anticoag w/in machine via Ca chelation. Citrate toxicity: ↓ iCa but nl/ ↑ serum Ca and AG met acidosis.</p>
<p class="noindent2">Dose adjust for solute and volume removal <span class="r1">(</span><span class="r2">AJKD</span> <span class="r1">2016;68:645)</span></p>
<p class="noindent1">• Other CRRT modalities: CVVHD (dialysis), CVVHDF (filtration &amp; dialysis) <span class="r1">(</span><span class="r2">AJKD</span> <span class="r1">2016;68:645)</span></p>
<p class="noindent1">• Benefits compared w/ HD: ↓ gross fluid shift (preferred in HoTN), but slower clearance of solutes and toxins</p>
<p class="h">Peritoneal dialysis (PD) <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2017;317:1864)</span></p>
<p class="noindent1">• Fluid removed via convection using oncotic pressure (eg, dextrose). ↑ concentrations and dwell times removes more fluid (less as glc equilibrates).</p>
<p class="noindent1">• PD fluid: dextrose (1.5%, 2.5%, or 4.25%), buffer (lactate), Na<sup class="calibre19">+</sup>, Ca<sup class="calibre19">2+</sup>, Mg<sup class="calibre19">2+</sup></p>
<p class="noindent1">• Infuse 10 min, dwell 90 min–5.5 h, drain 20 min; exchanges done manually or using cycler at night (automated or cont. ambulatory peritoneal dialysis APD, CAPD)</p>
<p class="noindent1">• PD peritonitis: abd pain &amp; cloudy drainage (WBC &gt;100 &amp; &gt;50% PMNs). 60–70% GPC, 15–20% GNR. Rx: abx IV or in PD, catheter removal for certain org (yeast, <i class="calibre6">Pseudomonas</i>).</p>
<p class="noindent1">• Sclerosing peritonitis, a rare long-term complication <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2002; 347:737)</span></p>
<p class="noindent1">• Hyperglycemia: exacerbated by inflammation, long dwell times, and higher [glucose]</p>
<p class="noindent1">• Benefits: lower cost, independence, preservation of residual kidney function. No Δ mortality vs. HD <span class="r1">(</span><span class="r2">AJKD</span> <span class="r1">2018;71:344)</span>.</p>
<p class="h">Kidney transplantation <span class="r1">(</span><span class="r2">Med Clin N Am</span> <span class="r1">2016;100:435)</span></p>
<p class="noindent1">• Refer when GFR &lt;20. Contraindic: active malig, infxn, ischemia, noncompl, subst use</p>
<p class="noindent1">• 5-yr survival: living donor 91%; deceased donor 70–84% <span class="r1">(</span><span class="r2">AJKD</span> <span class="r1">2016;23:281)</span><i class="calibre6">.</i> Donors have minor ↑ risk of ESRD <span class="r1">(</span><span class="r2">Am J Transplant</span> <span class="r1">2014;14:2434)</span>.</p>
<p class="noindent1">• Immunosuppression: calcineurin inhib (tacrolimus&gt;CsA) or CTLA4 inhib (belatacept) <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2016;374:333)</span>, antimetabolite (MMF&gt;AZA), prednisone, mTOR inhib (sirolimus) if others contraindicated</p>
<p class="noindent1">• Rejection: Ab (ABMR) or T-cell mediated (TCMR), a/w poor graft survival; BANFF criteria <span class="r1">(</span><span class="r2">Am J Transplant</span> <span class="r1">2018;18:293)</span>. Rx options: ↑ immunosupp., pulse steroids, IVIG, rituximab.</p>
<p class="noindent1">• Late renal dysfxn: usual AKI causes + calcineurin tox, rejection <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2010;363:1451)</span>, BK virus, recurrence of 1° disease; usual w/u + immunosupp levels, donor-specific antigen (DSA), BK virus load, U/S, then bx if no other cause <span class="r1">(</span><span class="r2">CJASN</span> <span class="r1">2008;3:S56;</span> <span class="r2">CJASN</span><span class="r1"> 2011;6:1774)</span></p>
<p class="noindent1">• ↑ infxn (incl opportunistic such as CMV, JC, BK viruses; <span class="r2">CJASN</span><span class="r1"> 2012;7:2058</span>) &amp; cancer (PTLD)</p>
<p class="noindent1">• ↑ CVD risk due to HTN (calcineurin inhib, RAS), DM &amp; dyslipidemia (immunosupp meds)</p>
<h2 class="ct"><a id="h59" class="calibre8"></a><a id="page_4-17" class="calibre8"></a><a href="part0003.html#rh66" class="calibre8">GLOMERULAR DISEASE</a></h2>
<p class="h1cr">G<small class="calibre31">LOMERULONEPHRITIS</small> (GN)</p>
<p class="h">Definition <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2016;387:2036;</span> <span class="r2">JASN</span> <span class="r1">2016;27:1278)</span></p>
<p class="noindent1">• ↑ glomerular inflammation → endothelial &amp; podocyte injury</p>
<p class="noindent1">• Histology: proliferative (↑ cells), sclerosing (scar), necrotizing (areas cell death). Focal (&lt;50% of glomeruli) to diffuse to crescentic. Segmental (&lt;50% tuft) to global (100%).</p>
<p class="noindent1">• Clinically: hematuria w/ dysmorphic RBCs or RBC casts, ± subnephrotic proteinuria often w/ AKI, HTN, edema</p>
<p class="noindent1">• Progression: acute ≈ days; rapidly progressive (RPGN) ~6 wk; chronic ≈ mos; can be asx</p>
<p class="imaget"><img src="../images/00072.jpeg" alt="" class="calibre5"/></p>
<p class="tfn"><sup class="calibre22"><a id="rfn81-a" class="calibre8"></a>a</sup>Predominant type; can see either type (<i class="calibre6">NEJM</i> 2012;367:214); <sup class="calibre22"><a id="rfn81-b" class="calibre8"></a>b</sup>GPA (Wegener’s); EGPA (Churg-Strauss)</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre23"/>
<col class="calibre23"/>
<col class="calibre23"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="4"><p class="tbodyc"><b class="calibre7">Anti-GBM Disease (linear staining)</b> &lt;1<b class="calibre7">5% of total</b> <span class="sm">(<i class="calibre6">CJASN</i> 2017;12:1162)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Disease</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Glomerulonephritis</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Pulm Hemorrhage</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Anti-GBM</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Goodpasture’s</b></p></td>
<td class="th1"><p class="tbodyc">⊕</p></td>
<td class="th1"><p class="tbodyc">⊕</p></td>
<td class="th1"><p class="tbodyc">⊕</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Anti-GBM disease</b></p></td>
<td class="th1"><p class="tbodyc">⊕</p></td>
<td class="th1"><p class="tbodyc">—</p></td>
<td class="th1"><p class="tbodyc">⊕</p></td>
</tr>
</tbody>
</table>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre26"/>
<col class="calibre26"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Immune Complex (IC) Disease (granular staining) ~40–45% of total</b> <span class="sm">(<i class="calibre6">CJASN</i> 2018;13:128)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Renal-Limited Diseases</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Systemic Diseases</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Infection-Related GN</b></p>
<p class="tbody">(<i class="calibre6">Staph</i> &amp; <i class="calibre6">Strep;</i> ↓ C3, ± ASLO)</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">SLE</b> <span class="sm">(<i class="calibre6">CJASN</i> 2017;12:825)</span></p>
<p class="tbody">(⊕ ANA, ⊕ anti-dsDNA, ⊕ anti-Sm, ↓ C3, ↓ C4)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Membranoproliferative GN</b> (MPGN) (↓ C3)</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Cryoglobulinemia</b></p>
<p class="tbody">(⊕ cryocrit, ⊕ RF, ⊕ HCV, SPEP, ↓ C3, ↓ C4)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Fibrillary and immunotactoid GN</b> (normal C3/C4)</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Endocarditis</b></p>
<p class="tbody">(fever, ⊕ BCx, valvular disease, ↓ C3)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">IgA nephropathy</b> (normal C3, ±↑ IgA)</p>
<p class="tbody"><span class="sm">(<i class="calibre6">NEJM</i> 2013;368:2402; <i class="calibre6">CJASN</i> 2017;12:677)</span></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Henoch-Schönlein purpura</b> (IgA nephropathy + syst. vasculitis w/ IgA deposits, nl C3, ±↑ IgA)</p></td>
</tr>
</tbody>
</table>
<p class="h">Oncology-related glomerulopathy <span class="r1">(</span><span class="r2">CJASN</span> <span class="r1">2016;11:1681)</span></p>
<p class="noindent1">• Associations between malig (solid tumors &amp; heme) and/or their Rx (HSCT &amp; chemo- therapeutics) and GN, nephrotic syndrome, and thrombotic microangiopathies (TMA)</p>
<p class="noindent1">• Most common associations: membranous (solid tumors, HSCT), MCD (Hodgkin’s, solid tumors), MPGN (CLL, MM), TMA (HSCT, VEGF, anti-EGFR, CNIs, TKIs, mTOR)</p>
<p class="noindent1">• <b class="calibre7">Monoclonal glomerulopathy of renal significance:</b> Ig-mediated kidney disease by nonmalignant B or plasma cells. Workup: SPEP, sFLC, flow cytometry, IFE, BMBx.</p>
<p class="h">Workup <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2017;318:1276)</span></p>
<p class="noindent1">• <i class="calibre6">Acute GN/RPGN</i> ±<i class="calibre6"> lung hemorrhage is an emergency</i> → requires early Dx and Rx</p>
<p class="noindent1">• UA + sediment (dysmorphic RBCs) ✓ ANCA, anti-GBM, C3/C4, SPEP, serum FLC</p>
<p class="noindent1">• Depending on hx: ANA, anti-dsDNA/Sm, RF, Hep B&amp;C, HIV, ASLO, BCx, cryocrit, skin bx</p>
<p class="noindent1">• Consider GN mimics: thrombotic microangiopathies (qv), myeloma, AIN, cholesterol emboli</p>
<p class="noindent1">• Renal biopsy with immunofluorescence (IF) + electron microscopy (EM)</p>
<div class="cap">
<p class="caption"><a id="fig4-8" class="calibre4"></a><b class="calibre7">Figure 4-8</b> Approach to glomerulonephritis based on immunofluorescence pattern</p>
<p class="imagef1"><img src="../images/00073.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="h"><a id="page_4-18" class="calibre4"></a>Treatment <span class="r1">(</span><span class="r2">AJKD</span> <span class="r1">2020;75:124 &amp; 2020;76:265)</span></p>
<p class="noindent1">• If acute GN/RPGN suspected, give 500–1000 mg methylpred. IV qd × 3d <i class="calibre6">ASAP</i> while awaiting bx results.</p>
<p class="noindent1">• SLE nephritis: induction w/ steroids + cyclophosphamide (CYC) or MMF <span class="r1">(</span><span class="r2">CJASN</span> <span class="r1">2017;12:825)</span></p>
<p class="noindent1">• ANCA ⊕ or anti-GBM: pulse steroids + CYC (or rituximab). Plasma exchange if ⊕ anti-GBM. Controversial in ANCA ⊕ only, even w/ GN or pulm hemor. <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2020;382:622)</span>.</p>
<p class="noindent1">• See “Vasculitis” for further disease-specific Rx details (eg, eculizumab for atypical HUS)</p>
<p class="h1cr">A<small class="calibre31">SYMPTOMATIC</small> G<small class="calibre31">LOMERULAR</small> H<small class="calibre31">EMATURIA</small></p>
<p class="h">Definition and etiologies</p>
<p class="noindent1">• Hematuria ± proteinuria of glomerular origin w/o renal insufficiency or systemic disease (nonglomerular more common; see “Hematuria”)</p>
<p class="noindent1">• Ddx: any cause of GN (esp. IgA); also consider Alport’s (X-linked, deafness, renal failure), thin basement membrane nephropathy (autosomal dominant, benign; <span class="r2">JASN</span><span class="r1"> 2013;23:364</span>)</p>
<p class="h">IgA nephropathy <span class="r1">(</span><span class="r2">CJASN</span> <span class="r1">2017;12:677;</span> <span class="r2">AJKD</span> <span class="r1">2021;78:429)</span></p>
<p class="noindent1">• Most common cause of GN; ♂ pred; peak incidence 20–30s; can also be post-infectious</p>
<p class="noindent1">• Wide range of clinical presentations: asx hematuria (30–40%), gross hematuria ~1–3 d after URI (10–15%), chronic GN (10%), nephrotic syndrome (5%), RPGN (&lt;5%)</p>
<p class="noindent1">• Though clinical presentation can be highly suggestive, definitive dx only w/ bx</p>
<p class="noindent1">• Prognosis: ↑Cr, HTN, proteinuria a/w poor prog. <span class="r1">(</span><span class="r2">AJKD</span> <span class="r1">2012;59:865)</span>. 20–40% ESRD w/in 20 y.</p>
<p class="noindent1">• Rx: ACEI/ARB; if persistent proteinuria (&gt; 1g/d), clinical trial enrollment or shared decision for steroids, consider SGLT2i <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2020;383:1436)</span>; ± cytotoxic Rx for GN; ? fish oil</p>
<p class="h1cr">N<small class="calibre31">EPHROTIC</small> S<small class="calibre31">YNDROME</small></p>
<p class="h">Definition <span class="r1">(</span><span class="r2">JASN</span> <span class="r1">2014;25:2393)</span></p>
<p class="noindent1">• Podocyte injury (effacement) → loss of proteins (albumin, ATIII, Ig)</p>
<p class="noindent1">• Clinically: proteinuria &gt;3.5 g/d, albumin &lt;3 g/dL, edema, ↑ chol., VTE (25%), infection</p>
<p class="h">Primary glomerular diseases (grouped by pathology)</p>
<p class="noindent1">• <b class="calibre7">Focal segmental glomerulosclerosis</b> (40%; <span class="r2">CJASN</span><span class="r1"> 2017;12:502</span>). <span class="underline">Primary</span>: permeability factor. <span class="underline">Secondary</span>: <i class="calibre6">adaptive</i> (hyperfiltration, sickle cell, obesity, anabolic steroids, OSA, ↑ protein, vesico-ureteral reflux); <i class="calibre6">meds/toxins</i> (IFN, bisphosphonates, NSAIDs, heroin), <i class="calibre6">viral</i> (COVID-19, HIV) or genetic (<i class="calibre6">ApoL1</i> mutation in AA; <span class="r2">JASN</span><span class="r1"> 2015;26:1443</span>).</p>
<p class="noindent1">• <b class="calibre7">Membranous nephropathy</b> (30%; <span class="r2">CJASN</span><span class="r1"> 2017;12:938,</span> <span class="r2">JASN</span><span class="r1"> 2021;32:268</span>): <span class="underline">Primary</span>: Ab to PLA2R [70%], THSD7A [5%], other (EXT1-2, NELL1, Sema3B). <span class="underline">Secondary</span>: <i class="calibre6">infxn</i> (HBV, HCV, HIV, syphilis); <i class="calibre6">autoimmune</i> (eg, SLE); <i class="calibre6">carcinomas</i>; <i class="calibre6">drugs</i> (NSAIDs, penicillamine).</p>
<p class="noindent1">• <b class="calibre7">Minimal change disease</b> (20%, more common in children; <span class="r2">CJASN</span><span class="r1"> 2017;12:332</span>) allergies, NSAIDs, ampicillin, Hodgkin’s disease, SLE, DM, MG, celiac disease</p>
<p class="noindent1">• <b class="calibre7">Membranoproliferative GN</b> (5%, <i class="calibre6">mixed</i> nephrotic/nephritic features; <span class="r2">CJASN</span><span class="r1"> 2014;9:600</span>)</p>
<p class="noindent2">Immune complex mediated: infection (esp. HCV ± cryos, IE, HBV, “shunt” nephritis, other chronic infxns), SLE, cryos, Sjögren’s, lymphomas, dysproteinemia, idiopathic</p>
<p class="noindent2">Complement mediated (rare); dense deposit disease (DDD), C3GN</p>
<p class="noindent1">• <b class="calibre7">Fibrillary-immunotactoid glomerulopathy</b> (1%; <span class="r2">JASN</span><span class="r1"> 2008;19:34</span>)</p>
<p class="noindent1">• <b class="calibre7">Mesangial proliferative GN</b> (? atypical forms of MCD/FSGS, 5%) IgM, C1q nephropathy</p>
<p class="h">Systemic diseases with secondary glomerular involvement</p>
<p class="noindent1">• <b class="calibre7">Diabetes mellitus</b> <span class="r1">(</span><span class="r2">CJASN</span> <span class="r1">2017;12:2032)</span>: nodular glomerulosclerosis (Kimmelstiel-Wilson lesion); glomerular hyperfiltration → microalbuminuria → dipstick ⊕ → nephrotic range (10–15 y). Proliferative retinopathy seen in 90% of type 1 and 60% of type 2.</p>
<p class="noindent1">• <b class="calibre7">Amyloidosis:</b> AL or light-chain amyloid or AA amyloid secondary to inflammation</p>
<p class="noindent1">• <b class="calibre7">SLE</b> <span class="r1">(</span><span class="r2">CJASN</span> <span class="r1">2017;12:825)</span>: typically membranous nephropathy (WHO class V)</p>
<p class="noindent1">• <b class="calibre7">Cryoglobulinemia</b> <span class="r1">(</span><span class="r2">AJKD</span> <span class="r1">2016;67)</span>: a/w HCV, monoclonal gammopathy. Typically MPGN.</p>
<p class="h">Workup <span class="r1">(</span><span class="r2">BMJ</span> <span class="r1">2008;336:1185)</span></p>
<p class="noindent1">• U/A + sediment: usually benign; ± oval fat bodies (“Maltese crosses”; <span class="r2">NEJM</span><span class="r1"> 2007;357:806</span>)</p>
<p class="noindent1">• Measure proteinuria: 24-h urine or spot urine protein/Cr ratio (not accurate in AKI), renal bx</p>
<p class="noindent1">• 2° causes: ↑ Hb<sub class="calibre10">A1C</sub> + retinop. → DM; ✓ ANA, anti-dsDNA, tox screen, C3/C4, SPEP/light chains, fat pad bx, cryocrit, HBV/HCV, HIV, RPR, APLA2R Ab, age-approp. CA screen</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2013;368:10)</span></p>
<p class="noindent1">• General: protein suppl.; diuretics for edema; treat hyperlipidemia, Na restriction (&lt;2 g/d)</p>
<p class="noindent1">• <b class="calibre7">ACEI</b> or <b class="calibre7">ARB:</b> ↓ proteinuria → slow nonimmunologic progression of renal disease</p>
<p class="noindent1">• 1° glomerular: steroids ± rituximab or cytotoxic therapy <span class="r1">(</span><span class="r2">CJASN</span> <span class="r1">2014;9:1386;</span> <span class="r2">NEJM</span> <span class="r1">2019;381:36)</span></p>
<p class="noindent1">• Secondary causes: treat underlying disease</p>
<p class="noindent1">• Watch for malnutrition (protein loss), consider anticoag if albumin &lt;2.5 in membranous <span class="r1">(</span><span class="r2">KI</span> <span class="r1">2014;85:1412)</span>, infection (esp. encapsulated organisms b/c loss of Ig)</p>
<h2 class="ct"><a id="h60" class="calibre8"></a><a id="page_4-19" class="calibre8"></a><a href="part0003.html#rh67" class="calibre8">URINALYSIS</a></h2>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre32"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Urine Dipstick</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Metric</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Significance and Uses</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Specific</b></p>
<p class="tbody"><b class="calibre7">gravity</b></p></td>
<td class="th1"><p class="tbody">Estimate U<sub class="calibre17">osm</sub>: each 0.001 above 1 ≈ 30 osm (SG 1.010 → U<sub class="calibre17">osm</sub> ≈ 300)</p>
<p class="tbody">SG and U<sub class="calibre17">osm</sub> useful in evaluating AKI, dysnatremias, polyuria Heavy substances (glucose, contrast) ↑ SG more than U<sub class="calibre17">osm</sub></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">pH</b></p></td>
<td class="th1"><p class="tbody">Range: 4.5–8.5; useful in evaluation of stones, RTAs, infection (urease UTI)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Protein</b></p></td>
<td class="th1"><p class="tbody">Detects albuminuria (&gt;300 mg/d); see “Proteinuria.” False ⊖: dilute urine</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Blood</b></p></td>
<td class="th1"><p class="tbody">See “Hematuria”; ⊕ from RBCs, free Hgb, or free myoglobin (eg, rhabdo)</p>
<p class="tbody">False ⊕: semen, dilute urine (→ osmotic cell lysis), ↑ pH, vaginal blood</p>
<p class="tbody">False ⊖: vit C</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">WBC</b></p></td>
<td class="th1"><p class="tbody">Suggests inflammation (UTI, interstitial nephritis, GN)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Ketones</b></p></td>
<td class="th1"><p class="tbody">Detects acetoacetate (ie, ketoacidosis) but <i class="calibre6">not</i> β-hydroxybutyrate</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Leuk est</b></p></td>
<td class="th1"><p class="tbody">Lysed PMNs. Se 80% for UTI. FN: proteinuria, glycosuria FP: ↓ pH or SG</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Nitrite</b></p></td>
<td class="th1"><p class="tbody">Suggests presence of nitrate reductase ⊕ bacteria (most enteric GNRs)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Bilirubin</b></p></td>
<td class="th1"><p class="tbody">↑ in biliary or hepatic disease</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Glucose</b></p></td>
<td class="th1"><p class="tbody">⊕ in hyperglycemia (&gt;180 mg/dL), pregnancy, Fanconi’s syndrome, SGLT2i</p></td>
</tr>
</tbody>
</table>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre32"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Urine Sediment (microscopic examination)</b> <span class="sm">(<i class="calibre6">Am J Kidney Dis</i> 2008;51:1052)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1" colspan="2"><p class="tbody"><b class="calibre7">Method:</b> Centrifuge fresh sample (prox. port if Foley) × 3–5 min at 1500–3000 rpm; pour off supernatant in one motion; resuspend pellet by agitating base of tube; pour suspension onto slide w/ coverslip; view under “high dry” power; phase contrast for RBC morphology</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Cells</b></p></td>
<td class="th1"><p class="tbody">RBCs: assess amount &amp; morphology (many dysmorphic → glomerular)</p>
<p class="tbody">WBCs: PMNs (UTI) vs. eosinophils (AIN; may require special stain)</p>
<p class="tbody">Epithelial cells: tubular (ATN), transitional (bladder or ureters), squamous</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Casts</b> <i class="calibre6">(see urinalysis photo inserts in appendix)</i></p></td>
<td class="th1"><p class="tbody"><i class="calibre6">Proteins molded in lumen of renal tubule</i> ± <i class="calibre6">entrapped cellular elements RBC</i> → <i class="calibre6">GN</i></p>
<p class="tbody">WBC → AIN, pyelonephritis, GN</p>
<p class="tbody">Granular (“muddy brown”): degenerating cellular casts → ATN</p>
<p class="tbody">Tubular cell → ATN</p>
<p class="tbody">Hyaline: Tamm-Horsfall protein (nonspecific)</p>
<p class="tbody">Waxy and broad → advanced chronic kidney disease</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Crystals</b></p>
<p class="tbody"><i class="calibre6">(see urinalysis photo inserts in appendix)</i></p></td>
<td class="th1"><p class="tbody">Calcium oxalate monohydrate: spindle, oval, or dumbbell shaped</p>
<p class="tbody">Calcium oxalate dihydrate: envelope shaped or octahedral</p>
<p class="tbody">Uric acid: variable shape; polychromatic under polarized light</p>
<p class="tbody">Cystine: hexagon shaped</p>
<p class="tbody">Struvite: coffin-lid shaped; seen in chronic UTI with urea-splitting organisms</p>
<p class="tbody">Drugs: sulfa, protease inhibitors: “shocks of wheat”; acyclovir: fine needles</p></td>
</tr>
</tbody>
</table>
<p class="h1cr">P<small class="calibre31">ROTEINURIA</small></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre33"/>
<col class="calibre18"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Etiologies of Proteinuria</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Category</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Description</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Etiologies</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Glomerular</b></p>
<p class="tbody">(can be &gt;3.5 g/d)</p></td>
<td class="th1"><p class="tbody">Disruption of filtration</p>
<p class="tbody">barrier → lose albumin</p></td>
<td class="th1"><p class="tbody">Glomerulonephritis</p>
<p class="tbody">Nephrotic syndrome</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Tubulointerstitial</b></p>
<p class="tbody">(usually &lt;1–2 g/d)</p></td>
<td class="th1"><p class="tbody">↓ reabsorption of freely filtered proteins → lose globulins</p></td>
<td class="th1"><p class="tbody">ATN; AIN</p>
<p class="tbody">Fanconi’s syndrome</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Overflow</b></p></td>
<td class="th1"><p class="tbody">↑ production of freely filtered proteins</p></td>
<td class="th1"><p class="tbody">Multiple myeloma</p>
<p class="tbody">Myoglobinuria</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Isolated</b></p></td>
<td class="th1"><p class="tbody">By def’n: asx, normal</p>
<p class="tbody">renal fxn, sed, &amp; imaging, no</p>
<p class="tbody">h/o renal disease</p></td>
<td class="th1"><p class="tbody">Functional (fever, exercise, CHF) Orthostatic (only when upright) Idiopathic (transient or persistent)</p></td>
</tr>
</tbody>
</table>
<p class="noindent1">• <b class="calibre7">Urine dipstick</b></p>
<p class="noindent2">1+ ≈30 mg/dL, 2+ ≈100 mg/dL, 3+ ≈300 mg/dL, 4+ &gt;2 g/dL; interpretation depends on SG; eg, 3+ in very concentrated urine might not indicate heavy proteinuria</p>
<p class="noindent2">Insensitive for microalbuminuria and myeloma light chains (Bence-Jones protein)</p>
<p class="noindent1">• <b class="calibre7">Spot urine:</b> protein (mg/dL)/creatinine (mg/dL) ≈ g/d of proteinuria <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">1983;309:1543)</span> unlike urine dipstick, will accurately measure myeloma light chains</p>
<p class="noindent2">reliable surrogate for 24-hr urine, esp. 1<sup class="calibre19">st</sup> morning void <span class="r1">(</span><span class="r2">JASN</span> <span class="r1">2009;20:436)</span>; inaccurate if AKI depends on Cr production, ∴ underestimates if muscular, overestimates if cachectic</p>
<p class="noindent1">• <b class="calibre7">Moderate albuminuria</b> (30–300 mg/d <i class="calibre6">or</i> mg/L <i class="calibre6">or</i> mg/g Cr): early sign of glomerular vascular disease; marker for ↑ risk of CV adverse outcomes <span class="r1">(</span><span class="r2">KI</span> <span class="r1">2013;3:19)</span></p>
<p class="noindent1"><a id="page_4-20" class="calibre4"></a>• Orthostatic proteinuria: typically in adolescents; ~90% of young ♂ with isolated proteinuria have orthostatic proteinuria; typically resolves spontaneously</p>
<p class="h1cr">H<small class="calibre31">EMATURIA</small></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre26"/>
<col class="calibre26"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Etiologies of Hematuria</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Extrarenal</b> (far more common)</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Intrarenal</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Nephrolithiasis</p>
<p class="tbody">Neoplasm: transitional cell, prostate</p>
<p class="tbody">Infxn: cystitis, urethritis, prostatitis</p>
<p class="tbody">Foley trauma</p>
<p class="tbody">BPH</p>
<p class="tbody">Schistosoma haematobium</p></td>
<td class="th1"><p class="tbody">Nephrolithiasis or crystalluria</p>
<p class="tbody">Neoplasm</p>
<p class="tbody">Trauma/exercise</p>
<p class="tbody">Vascular: renal infarcts, renal v. thromb., sickle cell</p>
<p class="tbody">Glomerular: IgA, thin BM, others</p>
<p class="tbody">PKD <span class="sm">(<i class="calibre6">NEJM</i> 2008;359:1477)</span></p></td>
</tr>
</tbody>
</table>
<p class="noindent1">• Wide, overlapping ages for various etiologies, but general guide for common causes:</p>
<p class="noindent2">&lt;20 y: GN, UTI, congenital; 20–60 y: UTI, nephrolithiasis, cancer</p>
<p class="noindent2">&gt;60 y ♂: prostatitis, cancer, UTI; &gt;60 y ♀: UTI, cancer</p>
<p class="h">Workup <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2021;385:153)</span></p>
<p class="noindent1">• <b class="calibre7">Urine dipstick:</b> ⊕ if ≥3 RBCs; ⊕ dipstick and ⊖ sediment → myo- or hemoglobinuria</p>
<p class="noindent1">• <b class="calibre7">Urine sediment:</b> dysmorphic RBCs or RBC casts → GN → consider renal bx</p>
<p class="noindent1">• If suggestive sx, r/o UTI or nephrolithiasis</p>
<p class="noindent1">• Low cancer risk: repeat U/A in 4–6 wks; if still ⊕ → cystoscopy + imaging</p>
<p class="noindent1">• Intermediate risk (eg, ♂ 40–59 yrs or ♀ 50–59 yrs or 10–30 pack-yrs): cystoscopy + U/S</p>
<p class="noindent1">• High risk (eg, age ≥60 or &gt;30 pack-yrs): CT urography (Se 96%, Sp 98%) + cystoscopy</p>
<p class="noindent1">• Rx: if obstruction: bladder irrigation and 3-way Foley on CBI</p>
<h2 class="ct"><a id="h61" class="calibre8"></a><a href="part0003.html#rh68" class="calibre8">NEPHROLITHIASIS</a></h2>
<p class="h">Types of stones and risk factors <span class="r1">(</span><span class="r2">Nat Rev Dis Prim</span> <span class="r1">2016;2:16008)</span></p>
<p class="noindent1">• <b class="calibre7">Calcium</b> (Ca oxalate &gt;Ca phosphate): <b class="calibre7">70–90% of kidney stones</b> <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2010;363:954)</span></p>
<p class="noindent2">Urine findings: ↑ Ca, ↑ oxalate (Ca-ox only), ↑ pH (Ca-phos only), ↓ citrate, ↓ volume</p>
<p class="noindent2">2° hypercalciuria: 1° hyperparathyroidism, distal RTA, sarcoid, Li use</p>
<p class="noindent2">2° hyperoxaluria: Crohn’s, ileal disease w/ intact colon, gastric bypass, pancreatic insuffic.</p>
<p class="noindent2">Diet: ↑ animal protein, ↑ sucrose, ↑ Na, ↓ K, ↓ fluid, ↓ fruits/vegetables, ↑ vit. C, ↓ Ca</p>
<p class="noindent1">• <b class="calibre7">Uric acid:</b> 5–10% of kidney stones, radiolucent on plain film</p>
<p class="noindent2">Urine findings: ↑ uric acid, ↓ pH (eg, from chronic diarrhea)</p>
<p class="noindent1">• <b class="calibre7">Magnesium ammonium phosphate</b> (“struvite” or “triple phosphate”)</p>
<p class="noindent2">Chronic upper UTI w/ urea-splitting organisms (eg, <i class="calibre6">Proteus, Klebs</i>) → ↑ urine NH<sub class="calibre10">3</sub>, pH &gt;7</p>
<p class="noindent1">• <b class="calibre7">Cystine:</b> inherited defects of tubular amino acid reabsorption</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Hematuria (absence does not exclude diagnosis), flank pain, N/V, dysuria, frequency</p>
<p class="noindent1">• Ureteral obstruction (stones &gt;5 mm unlikely to pass spont.) → AKI if solitary kidney</p>
<p class="noindent1">• UTI: ↑ risk of infection proximal to stone; urinalysis of distal urine may be normal</p>
<p class="h">Workup</p>
<p class="noindent1">• <b class="calibre7">Non-contrast CT</b> 97% Se, 96% Sp (ureteral dilation w/o stone suggests recent passage); U/S (Se 57%, Sp 98%) may serve as initial test in stable patient <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2014;371:1100)</span></p>
<p class="noindent1">• Strain urine for stone to analyze; U/A &amp; UCx; electrolytes, BUN/Cr, Ca, PO<sub class="calibre10">4</sub>, PTH</p>
<p class="noindent1">• 24-h urine × 2 (&gt;6 wk after acute setting) for Ca, PO<sub class="calibre10">4</sub>, oxalate, citrate, Na, Cr, pH, K, vol.</p>
<p class="h">Acute treatment <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2020;323:1961)</span></p>
<p class="noindent1">• Analgesia (narcotics ± NSAIDs; combination superior, <span class="r2">Ann Emerg Med</span> <span class="r1">2006;48:173</span>), ensure adequate fluid repletion, antibiotics if UTI</p>
<p class="noindent1">• α-blocker &gt;CCB to pass stone if ≤10 mm <span class="r1">(</span><span class="r2">Cochrane;</span> <span class="r1">2014:CD008509,</span> <span class="r2">Lancet</span><span class="r1"> 2006;368:1171)</span></p>
<p class="noindent1">• Indications for <b class="calibre7">immediate urologic eval and</b>/<b class="calibre7">or hosp:</b> obstruction (esp. solitary or transplant kidney), urosepsis, intractable pain or vomiting, significant AKI</p>
<p class="noindent1">• Urologic Rx: lithotripsy <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2012:367:50)</span>, ureteroscopic removal, lap/perc nephrolithotomy</p>
<p class="h">Chronic treatment <span class="r1">(</span><span class="r2">CJASN</span> <span class="r1">2016;11:1305 &amp; 2017;12:1699)</span></p>
<p class="noindent1">• Increase fluid intake (&gt;2 L/d) for goal UOP 2 L/d <span class="r1">(</span><span class="r2">J Nephrol</span> <span class="r1">2016;29:211)</span></p>
<p class="noindent1">• Calcium stones: 24-h urine identifies <b class="calibre7">specific urinary risk factors to treat</b></p>
<p class="noindent2">Diet: ↓ Na and meat <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2002;346:77)</span>, ↓ oxalate foods &amp; sucrose/fructose</p>
<p class="noindent2">Meds: thiazides (↓ urine Ca), K-citrate if low urine citrate, allopurinol if high urine uric acid</p>
<p class="noindent2">Avoid low dietary Ca as ↑ oxalate absorp <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2002;346:77)</span>, unclear role of Ca suppl.</p>
<p class="noindent1">• Uric acid: fluid intake, urine alkalinization (K-citrate) to pH 6.5–7, allopurinol</p>
<p class="noindent1">• Magnesium ammonium phosphate (struvite): antibiotics for UTI; urologic intervention; acetohydroxamic acid; urease inhibitor reserved for experienced clinician, poorly tolerated</p>
<p class="noindent1">• Cystine: fluid, urine alkaliniz (K-citrate) to 7–8, d-penicillamine, tiopronin <span class="r1">(</span><span class="r2">KI</span> <span class="r1">2006;69:1041)</span></p>


  </div>

  
  <div class="calibreToc">
    <h2><a href="../../j09u21sl.html">Table of contents
</a></h2>
    <div>
  <ul>
    <li>
      <a href="part0000.html#0-96ac16803db7461d85d0589a1c192bcf">Cover</a>
    </li>
    <li>
      <a href="part0001.html#UGI0-96ac16803db7461d85d0589a1c192bcf">Title Page</a>
    </li>
    <li>
      <a href="part0002.html#1T140-96ac16803db7461d85d0589a1c192bcf">Copyright Page</a>
    </li>
    <li>
      <a href="part0003.html#2RHM0-96ac16803db7461d85d0589a1c192bcf">Contents</a>
    </li>
    <li>
      <a href="part0004.html#3Q280-96ac16803db7461d85d0589a1c192bcf">Contributing Authors</a>
    </li>
    <li>
      <a href="part0005.html#4OIQ0-96ac16803db7461d85d0589a1c192bcf">Foreword</a>
    </li>
    <li>
      <a href="part0006.html#5N3C0-96ac16803db7461d85d0589a1c192bcf">Preface</a>
    </li>
    <li>
      <a href="part0007.html#6LJU0-96ac16803db7461d85d0589a1c192bcf">CARDIOLOGY</a>
      <ul>
        <li>
          <a href="part0007.html#h1">Electrocardiography</a>
        </li>
        <li>
          <a href="part0007.html#h2">Chest Pain</a>
        </li>
        <li>
          <a href="part0007.html#h3">Noninvasive Evaluation of CAD</a>
        </li>
        <li>
          <a href="part0007.html#h4">Coronary Angiography &amp; PCI</a>
        </li>
        <li>
          <a href="part0007.html#h5">Stable Ischemic Heart Disease</a>
        </li>
        <li>
          <a href="part0007.html#h6">Acute Coronary Syndromes</a>
        </li>
        <li>
          <a href="part0007.html#h7">PA Catheter and Tailored Therapy</a>
        </li>
        <li>
          <a href="part0007.html#h8">Heart Failure</a>
        </li>
        <li>
          <a href="part0007.html#h9">Cardiomyopathies</a>
        </li>
        <li>
          <a href="part0007.html#h10">Valvular Heart Disease</a>
        </li>
        <li>
          <a href="part0007.html#h11">Pericardial Disease</a>
        </li>
        <li>
          <a href="part0007.html#h12">Hypertension</a>
        </li>
        <li>
          <a href="part0007.html#h13">Aortic Aneurysms</a>
        </li>
        <li>
          <a href="part0007.html#h14">Acute Aortic Syndromes</a>
        </li>
        <li>
          <a href="part0007.html#h15">Arrhythmias</a>
        </li>
        <li>
          <a href="part0007.html#h16">Atrial Fibrillation</a>
        </li>
        <li>
          <a href="part0007.html#h17">Syncope</a>
        </li>
        <li>
          <a href="part0007.html#h18">Cardiac Rhythm Management Devices</a>
        </li>
        <li>
          <a href="part0007.html#h19">Cardiac Risk Assessment for Noncardiac Surgery</a>
        </li>
        <li>
          <a href="part0007.html#h20">Peripheral Artery Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0008.html#7K4G0-96ac16803db7461d85d0589a1c192bcf">PULMONARY</a>
      <ul>
        <li>
          <a href="part0008.html#h21">Dyspnea</a>
        </li>
        <li>
          <a href="part0008.html#h22">Pulmonary Function Tests</a>
        </li>
        <li>
          <a href="part0008.html#h23">Asthma</a>
        </li>
        <li>
          <a href="part0008.html#h24">Anaphylaxis</a>
        </li>
        <li>
          <a href="part0008.html#h25">Chronic Obstructive Pulmonary Disease</a>
        </li>
        <li>
          <a href="part0008.html#h26">Solitary Pulmonary Nodule</a>
        </li>
        <li>
          <a href="part0008.html#h27">Hemoptysis</a>
        </li>
        <li>
          <a href="part0008.html#h28">Bronchiectasis</a>
        </li>
        <li>
          <a href="part0008.html#h29">Cystic Fibrosis</a>
        </li>
        <li>
          <a href="part0008.html#h30">Interstitial Lung Disease</a>
        </li>
        <li>
          <a href="part0008.html#h31">Pleural Effusion</a>
        </li>
        <li>
          <a href="part0008.html#h32">Venous Thromboembolism</a>
        </li>
        <li>
          <a href="part0008.html#h33">Pulmonary Hypertension</a>
        </li>
        <li>
          <a href="part0008.html#h34">Respiratory Failure</a>
        </li>
        <li>
          <a href="part0008.html#h35">Mechanical Ventilation</a>
        </li>
        <li>
          <a href="part0008.html#h36">Acute Respiratory Distress Syndrome</a>
        </li>
        <li>
          <a href="part0008.html#h37">Sepsis and Shock</a>
        </li>
        <li>
          <a href="part0008.html#h38">Toxicology</a>
        </li>
        <li>
          <a href="part0008.html#h39">Lung Transplant</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0009.html#8IL20-96ac16803db7461d85d0589a1c192bcf">GASTROENTEROLOGY</a>
      <ul>
        <li>
          <a href="part0009.html#h40">Esophageal and Gastric Disorders</a>
        </li>
        <li>
          <a href="part0009.html#h41">Gastrointestinal Bleeding</a>
        </li>
        <li>
          <a href="part0009.html#h42">Diarrhea</a>
        </li>
        <li>
          <a href="part0009.html#h43">Dysmotility &amp; Nutrition</a>
        </li>
        <li>
          <a href="part0009.html#h44">Disorders of the Colon</a>
        </li>
        <li>
          <a href="part0009.html#h45">Inflammatory Bowel Disease</a>
        </li>
        <li>
          <a href="part0009.html#h46">Intestinal Ischemia</a>
        </li>
        <li>
          <a href="part0009.html#h47">Pancreatitis</a>
        </li>
        <li>
          <a href="part0009.html#h48">Abnormal Liver Tests</a>
        </li>
        <li>
          <a href="part0009.html#h49">Hepatitis</a>
        </li>
        <li>
          <a href="part0009.html#h50">Acute Liver Failure</a>
        </li>
        <li>
          <a href="part0009.html#h51">Cirrhosis</a>
        </li>
        <li>
          <a href="part0009.html#h52">Hepatic Vascular Disease</a>
        </li>
        <li>
          <a href="part0009.html#h53">Ascites</a>
        </li>
        <li>
          <a href="part0009.html#h54">Biliary Tract Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0010.html#9H5K0-96ac16803db7461d85d0589a1c192bcf">NEPHROLOGY</a>
      <ul>
        <li>
          <a href="part0010.html#h55">Acid-Base Disturbances</a>
        </li>
        <li>
          <a href="part0010.html#h56">Sodium and Water Homeostasis</a>
        </li>
        <li>
          <a href="part0010.html#h57">Potassium Homeostasis</a>
        </li>
        <li>
          <a href="part0010.html#h58">Kidney Disease</a>
        </li>
        <li>
          <a href="part0010.html#h59">Glomerular Disease</a>
        </li>
        <li>
          <a href="part0010.html#h60">Urinalysis</a>
        </li>
        <li>
          <a href="part0010.html#h61">Nephrolithiasis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0011.html#AFM60-96ac16803db7461d85d0589a1c192bcf">HEMATOLOGY-ONCOLOGY</a>
      <ul>
        <li>
          <a href="part0011.html#h62">Anemia</a>
        </li>
        <li>
          <a href="part0011.html#h63">Disorders of Hemostasis</a>
        </li>
        <li>
          <a href="part0011.html#h64">Platelet Disorders</a>
        </li>
        <li>
          <a href="part0011.html#h65">Coagulopathies</a>
        </li>
        <li>
          <a href="part0011.html#h66">Hypercoagulable States</a>
        </li>
        <li>
          <a href="part0011.html#h67">Disorders of Leukocytes</a>
        </li>
        <li>
          <a href="part0011.html#h68">Transfusion Therapy</a>
        </li>
        <li>
          <a href="part0011.html#h69">Myelodysplastic Syndromes</a>
        </li>
        <li>
          <a href="part0011.html#h70">Myeloproliferative Neoplasms</a>
        </li>
        <li>
          <a href="part0011.html#h71">Leukemia</a>
        </li>
        <li>
          <a href="part0011.html#h72">Lymphoma and CLL</a>
        </li>
        <li>
          <a href="part0011.html#h73">Plasma Cell Dyscrasias</a>
        </li>
        <li>
          <a href="part0011.html#h74">Hematopoietic Stem Cell Transplantation</a>
        </li>
        <li>
          <a href="part0011.html#h75">Lung Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h76">Breast Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h77">Prostate Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h78">Colorectal Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h79">Pancreatic Tumors</a>
        </li>
        <li>
          <a href="part0011.html#h80">Other Solid Tumors</a>
        </li>
        <li>
          <a href="part0011.html#h81">Immunotherapy &amp; Cellular Therapy</a>
        </li>
        <li>
          <a href="part0011.html#h82">Oncologic Emergencies</a>
        </li>
        <li>
          <a href="part0011.html#h83">Chemo Side Effects</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0012.html#BE6O0-96ac16803db7461d85d0589a1c192bcf">INFECTIOUS DISEASES</a>
      <ul>
        <li>
          <a href="part0012.html#h84">Pneumonia</a>
        </li>
        <li>
          <a href="part0012.html#h85">Fungal Infections</a>
        </li>
        <li>
          <a href="part0012.html#h86">Infxns in Immunosuppressed Hosts</a>
        </li>
        <li>
          <a href="part0012.html#h87">Urinary Tract Infections</a>
        </li>
        <li>
          <a href="part0012.html#h88">Sexually Transmitted Infections</a>
        </li>
        <li>
          <a href="part0012.html#h89">Skin and Soft Tissue Infections</a>
        </li>
        <li>
          <a href="part0012.html#h90">Infections of the Nervous System</a>
        </li>
        <li>
          <a href="part0012.html#h91">Bacteremia &amp; Endocarditis</a>
        </li>
        <li>
          <a href="part0012.html#h92">Tuberculosis</a>
        </li>
        <li>
          <a href="part0012.html#h93">HIV/AIDS</a>
        </li>
        <li>
          <a href="part0012.html#h94">Tick-Borne Diseases</a>
        </li>
        <li>
          <a href="part0012.html#h95">Fever Syndromes</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0013.html#CCNA0-96ac16803db7461d85d0589a1c192bcf">ENDOCRINOLOGY</a>
      <ul>
        <li>
          <a href="part0013.html#h96">Pituitary Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h97">Thyroid Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h98">Adrenal Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h99">Calcium Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h100">Diabetes Mellitus</a>
        </li>
        <li>
          <a href="part0013.html#h101">Lipid Disorders</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0014.html#DB7S0-96ac16803db7461d85d0589a1c192bcf">RHEUMATOLOGY</a>
      <ul>
        <li>
          <a href="part0014.html#h102">Approach to Rheumatic Disease</a>
        </li>
        <li>
          <a href="part0014.html#h103">Rheumatoid Arthritis</a>
        </li>
        <li>
          <a href="part0014.html#h104">Adult-Onset Still’s Disease &amp; Relapsing Polychondritis</a>
        </li>
        <li>
          <a href="part0014.html#h105">Crystal Deposition Arthritides</a>
        </li>
        <li>
          <a href="part0014.html#h106">Seronegative Spondyloarthritis</a>
        </li>
        <li>
          <a href="part0014.html#h107">Infectious Arthritis &amp; Bursitis</a>
        </li>
        <li>
          <a href="part0014.html#h108">Connective Tissue Diseases</a>
        </li>
        <li>
          <a href="part0014.html#h109">Systemic Lupus Erythematosus</a>
        </li>
        <li>
          <a href="part0014.html#h110">IgG4-Related Disease</a>
        </li>
        <li>
          <a href="part0014.html#h111">Vasculitis</a>
        </li>
        <li>
          <a href="part0014.html#h112">Autoinflammatory Syndromes</a>
        </li>
        <li>
          <a href="part0014.html#h113">Amyloidosis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0015.html#E9OE0-96ac16803db7461d85d0589a1c192bcf">NEUROLOGY</a>
      <ul>
        <li>
          <a href="part0015.html#h114">Change in Mental Status</a>
        </li>
        <li>
          <a href="part0015.html#h115">Seizures</a>
        </li>
        <li>
          <a href="part0015.html#h116">Alcohol Withdrawal</a>
        </li>
        <li>
          <a href="part0015.html#h117">Dizziness</a>
        </li>
        <li>
          <a href="part0015.html#h118">Stroke</a>
        </li>
        <li>
          <a href="part0015.html#h119">Weakness &amp; Neuromuscular Dysfunction</a>
        </li>
        <li>
          <a href="part0015.html#h120">Headache</a>
        </li>
        <li>
          <a href="part0015.html#h121">Back and Spinal Cord Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0016.html#F8900-96ac16803db7461d85d0589a1c192bcf">CONSULTS</a>
      <ul>
        <li>
          <a href="part0016.html#h122">Surgical Issues</a>
        </li>
        <li>
          <a href="part0016.html#h123">Ob/Gyn Issues</a>
        </li>
        <li>
          <a href="part0016.html#h124">Ophthalmic Issues</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0017.html#G6PI0-96ac16803db7461d85d0589a1c192bcf">APPENDIX</a>
      <ul>
        <li>
          <a href="part0017.html#h125">ICU Medications</a>
        </li>
        <li>
          <a href="part0017.html#h126">Antibiotics</a>
        </li>
        <li>
          <a href="part0017.html#h127">Formulae and Quick Reference</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0018.html#H5A40-96ac16803db7461d85d0589a1c192bcf">ABBREVIATIONS</a>
    </li>
    <li>
      <a href="part0019.html#I3QM0-96ac16803db7461d85d0589a1c192bcf">INDEX</a>
    </li>
    <li>
      <a href="part0020.html#J2B80-96ac16803db7461d85d0589a1c192bcf">PHOTO INSERTS</a>
      <ul>
        <li>
          <a href="part0020.html#h128">Radiology</a>
        </li>
        <li>
          <a href="part0020.html#h129">Echocardiography</a>
        </li>
        <li>
          <a href="part0020.html#h130">Coronary Angiography</a>
        </li>
        <li>
          <a href="part0020.html#h131">Peripheral Blood Smears</a>
        </li>
        <li>
          <a href="part0020.html#h132">Leukemias</a>
        </li>
        <li>
          <a href="part0020.html#h133">Urinalysis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0021.html#K0RQ0-96ac16803db7461d85d0589a1c192bcf">ACLS</a>
    </li>
  </ul>
</div>


  </div>
  

  <div class="calibreEbNav">
    
      <a href="part0009.html" class="calibreAPrev">previous page
</a>
    

    <a href="../../j09u21sl.html" class="calibreAHome">start
</a>

    
      <a href="part0011.html" class="calibreANext">next page
</a>
    
  </div>

</div>

</body>
</html>
